|
|
| Zeile 1: |
Zeile 1: |
| | [[TempP(3)]] | | [[TempP(3)]] |
| − |
| |
| − |
| |
| − | {{tp|p=32904593|t=2020. A Single Large Dose of Vitamin D Could be Used as a Means of Coronavirus Disease 2019 Prevention and Treatment.|pdf=|usr=019}}
| |
| − | {{tp|p=32949526|t=2020. Taming the cytokine storm: repurposing montelukast for the attenuation and prophylaxis of severe COVID-19 symptoms.|pdf=|usr=019}}
| |
| − | {{tp|p=32947043|t=2020. Chloroquine against malaria, cancers and viral diseases.|pdf=|usr=019}}
| |
| − | {{tp|p=32997318|t=2020. Assessing the Safety of COVID-19 Vaccines: A Primer.|pdf=|usr=019}}
| |
| − | {{tp|p=32978702|t=2020. Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports.|pdf=|usr=019}}
| |
| − | {{tp|p=33014097|t=2020. Dabigatran, the oral anticoagulant of choice at discharge in patients with non-valvular atrial fibrillation and COVID-19 infection: the ANIBAL protocol.|pdf=|usr=019}}
| |
| − | {{tp|p=32952393|t=2020. Severe prolonged neutropenia following administration of tocilizumab in a patient affected by COVID-19: a case report and brief review of the literature.|pdf=|usr=019}}
| |
| − | {{tp|p=32951446|t=2020. Efficacy of Povidone-Iodine Nasal and Oral Antiseptic Preparations Against Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2).|pdf=|usr=019}}
| |
| − | {{tp|p=32950003|t=2020. Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: A prospective cohort study.|pdf=|usr=019}}
| |
| − | {{tp|p=33014130|t=2020. Possible mechanisms of action of clarithromycin and its clinical application as a repurposing drug for treating multiple myeloma.|pdf=|usr=019}}
| |
| − | {{tp|p=32984784|t=2020. An open-label, randomized trial of the combination of IFN-kappa plus TFF2 with standard care in the treatment of patients with moderate COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32837997|t=2020. Convalescent plasma to treat COVID-19: Its challenges in Iraq's situation.|pdf=|usr=019}}
| |
| − | {{tp|p=32933891|t=2020. Interleukin-6 and severe COVID-19: a systematic review and meta-analysis.|pdf=|usr=019}}
| |
| − | {{tp|p=32984253|t=2020. Importance of Dietary Changes During the Coronavirus Pandemic: How to Upgrade Your Immune Response.|pdf=|usr=019}}
| |
| − | {{tp|p=32984235|t=2020. Ozone Therapy as a Possible Option in COVID-19 Management.|pdf=|usr=019}}
| |
| − | {{tp|p=32951474|t=2020. Potential alteration of COVID-19 by beta-mercaptoethanol.|pdf=|usr=019}}
| |
| − | {{tp|p=32974048|t=2020. Cannabis for COVID-19: can cannabinoids quell the cytokine storm?|pdf=|usr=019}}
| |
| − | {{tp|p=32946905|t=2020. INTESTINAL MICROBIOME MODULATION DURING COVID-19: ANOTHER CHANCE TO MANAGE THE DISEASE?|pdf=|usr=019}}
| |
| − | {{tp|p=32920121|t=2020. SARS-CoV-2 transcriptome analysis and molecular cataloguing of immunodominant epitopes for multi-epitope based vaccine design.|pdf=|usr=019}}
| |
| − | {{tp|p=32943258|t=2020. Vitamin D dosing considerations in COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32923351|t=2020. Cardiometabolic Health: Key in Reducing Adverse COVID-19 Outcomes.|pdf=|usr=019}}
| |
| − | {{tp|p=33003439|t=2020. Evaluation of Country Dietary Habits Using Machine Learning Techniques in Relation to Deaths from COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=33010945|t=2020. SGLT-2 inhibitors as cardioprotective agents in COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32980171|t=2020. Anti-inflammatory aspects of Lidocaine: a neglected therapeutic stance for COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32911459|t=2020. Promising impacts of mesenchymal stem cell therapy in treatment of SARS-CoV-2 (COVID-19).|pdf=|usr=019}}
| |
| − | {{tp|p=32984620|t=2020. Nucleic acid-based therapy for coronavirus disease 2019.|pdf=|usr=019}}
| |
| − | {{tp|p=32935064|t=2020. Chloroquine to fight COVID-19: A consideration of mechanisms and adverse effects?|pdf=|usr=019}}
| |
| − | {{tp|p=32929412|t=2020. A systematic review on COVID-19 pandemic with special emphasis on curative potentials of Nigeria based medicinal plants.|pdf=|usr=019}}
| |
| − | {{tp|p=32923731|t=2020. An immunoinformatics study on the spike protein of SARS-CoV-2 revealing potential epitopes as vaccine candidates.|pdf=|usr=019}}
| |
| − | {{tp|p=33020742|t=2020. Novel hybrid antiviral VTRRT-13V2.1 against SARS-CoV2 main protease: retro-combinatorial synthesis and molecular dynamics analysis.|pdf=|usr=019}}
| |
| − | {{tp|p=32943233|t=2020. Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab.|pdf=|usr=019}}
| |
| − | {{tp|p=33006053|t=2020. Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development.|pdf=|usr=019}}
| |
| − | {{tp|p=32946016|t=2020. Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine.|pdf=|usr=019}}
| |
| − | {{tp|p=32900263|t=2020. Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins.|pdf=|usr=019}}
| |
| − | {{tp|p=32773424|t=2020. Effect of quantitative real-time RT-PCR reaction sensitivity in determining the efficacy of HCQ prophylaxis for COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=33012868|t=2020. Diet, Gut Microbiota and COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=33013067|t=2020. Anti-corona Drugs: Current Scenario.|pdf=|usr=019}}
| |
| − | {{tp|p=32989938|t=2020. Convalescent Plasma Therapy for Coronavirus Disease 2019.|pdf=|usr=019}}
| |
| − | {{tp|p=32986226|t=2020. Effect of Corticosteroid Therapy on the Duration of SARS-CoV-2 Clearance in Patients with Mild COVID-19: A Retrospective Cohort Study.|pdf=|usr=019}}
| |
| − | {{tp|p=32983830|t=2020. Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase II Clinical Trial.|pdf=|usr=019}}
| |
| − | {{tp|p=32953385|t=2020. Steroids and COVID-19: We Need a Precision Approach, Not One Size Fits All.|pdf=|usr=019}}
| |
| − | {{tp|p=32943888|t=2020. Design an Efficient Multi-Epitope Peptide Vaccine Candidate Against SARS-CoV-2: An in silico Analysis.|pdf=|usr=019}}
| |
| − | {{tp|p=32920586|t=2020. Granulocyte colony-stimulating factors (G-CSF) and Covid-19: a double-edged sword?|pdf=|usr=019}}
| |
| − | {{tp|p=32920571|t=2020. The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq.|pdf=|usr=019}}
| |
| − | {{tp|p=32921678|t=2020. Suspected Hydroxychloroquine-Induced Sinus Bradycardia and QTc Prolongation in a Patient with COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32919216|t=2020. Drug repurposing and cytokine management in response to COVID-19: A review.|pdf=|usr=019}}
| |
| − | {{tp|p=32896750|t=2020. Immunomodulatory-based therapy as a potential promising treatment strategy against severe COVID-19 patients: A systematic review.|pdf=|usr=019}}
| |
| − | {{tp|p=32987103|t=2020. Design of novel viral attachment inhibitors of the spike glycoprotein (S) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) through virtual screening and dynamics.|pdf=|usr=019}}
| |
| − | {{tp|p=32991900|t=2020. Novel insights into the treatment of SARS-CoV-2 infection: An overview of current clinical trials.|pdf=|usr=019}}
| |
| − | {{tp|p=32980406|t=2020. Evaluation of the potency of FDA-approved drugs on wild type and mutant SARS-CoV-2 helicase (Nsp13).|pdf=|usr=019}}
| |
| − | {{tp|p=32979436|t=2020. The structure-activity relationship of the interactions of SARS-CoV-2 spike glycoproteins with glucuronomannan and sulfated galactofucan from Saccharina japonica.|pdf=|usr=019}}
| |
| − | {{tp|p=32950529|t=2020. Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach.|pdf=|usr=019}}
| |
| − | {{tp|p=32956782|t=2020. Assessing QT interval in COVID-19 patients:safety of hydroxychloroquine-azithromycin combination regimen.|pdf=|usr=019}}
| |
| − | {{tp|p=32974857|t=2020. The therapeutic effects of traditional chinese medicine on COVID-19: a narrative review.|pdf=|usr=019}}
| |
| − | {{tp|p=32898838|t=2020. Nasal disinfection for the prevention and control of COVID-19: A scoping review on potential chemo-preventive agents.|pdf=|usr=019}}
| |
| − | {{tp|p=32911042|t=2020. Analysis of the predictive factors for a critical illness of COVID-19 during treatment relationship between serum zinc level and critical illness of COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=33007455|t=2020. COX2 inhibition in the treatment of COVID-19: Review of literature to propose repositioning of celecoxib for randomized controlled studies.|pdf=|usr=019}}
| |
| − | {{tp|p=33007454|t=2020. Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients.|pdf=|usr=019}}
| |
| − | {{tp|p=33007453|t=2020. Use of hydroxychloroquine and chloroquine in COVID-19: How good is the quality of randomized controlled trials?|pdf=|usr=019}}
| |
| − | {{tp|p=33002613|t=2020. Tocilizumab therapy for COVID-19: A comparison of subcutaneous and intravenous therapies.|pdf=|usr=019}}
| |
| − | {{tp|p=33002611|t=2020. Effect of convalescent blood products for patients with severe acute respiratory infections of viral etiology: a systematic review and meta-analysis.|pdf=|usr=019}}
| |
| − | {{tp|p=32992014|t=2020. Favipiravir-induced fever in coronavirus disease 2019: A report of two cases.|pdf=|usr=019}}
| |
| − | {{tp|p=32980554|t=2020. NOD2-dependent BCG-induced trained immunity: A way to regulate innate responses to SARS-CoV2?|pdf=|usr=019}}
| |
| − | {{tp|p=32920234|t=2020. COVID-19: Poor outcomes in patients with zinc deficiency.|pdf=|usr=019}}
| |
| − | {{tp|p=33011285|t=2020. Finding the right time for anti-inflammatory therapy in COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=33014624|t=2020. COVID-19 and Child Vaccination: A Systematic Approach to Closing the Immunization Gap.|pdf=|usr=019}}
| |
| − | {{tp|p=32922174|t=2020. COVID-19: Rational discovery of the therapeutic potential of Melatonin as a SARS-CoV-2 main Protease Inhibitor.|pdf=|usr=019}}
| |
| − | {{tp|p=32963540|t=2020. Possible Role for Bacteriophages in the Treatment of SARS-CoV-2 Infection.|pdf=|usr=019}}
| |
| − | {{tp|p=33000193|t=2020. [Comment] COVID19 vaccine safety.|pdf=|usr=019}}
| |
| − | {{tp|p=32899381|t=2020. State of the Art Review of Cell Therapy in the Treatment of Lung Disease, and the Potential for Aerosol Delivery.|pdf=|usr=019}}
| |
| − | {{tp|p=32899231|t=2020. The HMOX1 Pathway as a Promising Target for the Treatment and Prevention of SARS-CoV-2 of 2019 (COVID-19).|pdf=|usr=019}}
| |
| − | {{tp|p=33003377|t=2020. Targeting the SphK-S1P-SIPR Pathway as a Potential Therapeutic Approach for COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32957696|t=2020. Stem Cells Secretome from Oral Tissue Could Represent a Promising Therapeutic Approach in COVID-19-Disease?|pdf=|usr=019}}
| |
| − | {{tp|p=32942748|t=2020. SARS-CoV-2 Infection: A Role for S1P/S1P Receptor Signaling in the Nervous System?|pdf=|usr=019}}
| |
| − | {{tp|p=33013255|t=2020. Screening of FDA Approved Drugs Against SARS-CoV-2 Main Protease: Coronavirus Disease.|pdf=|usr=019}}
| |
| − | {{tp|p=32935062|t=2020. Prospective data linkage to facilitate COVID-19 trials - A call to action.|pdf=|usr=019}}
| |
| − | {{tp|p=32939238|t=2020. Hypothesis of COVID-19 Therapy with Sildenafil.|pdf=|usr=019}}
| |
| − | {{tp|p=33011212|t=2020. Pneumonia After Bacterial or Viral Infection Preceded or Followed by Radiation Exposure: A Reanalysis of Older Radiobiologic Data and Implications for Low Dose Radiation Therapy for Coronavirus Disease 2019 Pneumonia.|pdf=|usr=019}}
| |
| − | {{tp|p=32896649|t=2020. Dexamethasone to combat cytokine storm in COVID-19: Clinical trials and preliminary evidence.|pdf=|usr=019}}
| |
| − | {{tp|p=32913393|t=2020. Possible role of tryptophan and melatonin in COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32946004|t=2020. Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak.|pdf=|usr=019}}
| |
| − | {{tp|p=32983864|t=2021. The efficacy and safety of traditional Chinese medicines, modified Radix Fici Simplicissimae, combined with Western medicines amongst patients infected with the 2019 novel coronavirus (SARS-CoV-2) in tropical tourist area, China.|pdf=|usr=019}}
| |
| − | {{tp|p=32955678|t=2020. Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option? Reply.|pdf=|usr=019}}
| |
| − | {{tp|p=33011928|t=2020. Protective role of statins in COVID 19 patients: importance of pharmacokinetic characteristics rather than intensity of action.|pdf=|usr=019}}
| |
| − | {{tp|p=32997237|t=2020. The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients.|pdf=|usr=019}}
| |
| − | {{tp|p=32915341|t=2020. The use of antioxidants against high ferritin-induced oxidation in COVID-19 patients: a biochemical approach.|pdf=|usr=019}}
| |
| − | {{tp|p=32964056|t=2020. Attenuated Subcomponent Vaccine Design Targeting the SARS-CoV-2 Nucleocapsid Phosphoprotein RNA Binding Domain: In Silico Analysis.|pdf=|usr=019}}
| |
| − | {{tp|p=32931775|t=2020. The association between corticosteroid uses and mortality among severe COVID-19 patients.|pdf=|usr=019}}
| |
| − | {{tp|p=32988730|t=2020. Corticosteroids as adjunctive therapy in the treatment of coronavirus disease 2019: A report of two cases and literature review.|pdf=|usr=019}}
| |
| − | {{tp|p=32893123|t=2020. Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate.|pdf=|usr=019}}
| |
| − | {{tp|p=32903227|t=2020. Can Levamisole be used in the treatment of COVID-19 patients presenting with diarrhea?|pdf=|usr=019}}
| |
| − | {{tp|p=32948484|t=2020. Opinions on the current pandemic of COVID-19: Use functional food to boost our immune functions.|pdf=|usr=019}}
| |
| − | {{tp|p=32900666|t=2020. Positive aspects, negative aspects and limitations of plasma therapy with special reference to COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=33008778|t=2020. Association of corticosteroids use and outcomes in COVID-19 patients: A systematic review and meta-analysis.|pdf=|usr=019}}
| |
| − | {{tp|p=33008777|t=2020. In silico molecular docking: Evaluation of coumarin based derivatives against SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=32972277|t=2020. Mesenchymal stem cell research progress for the treatment of COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32962495|t=2020. Possible effect of epinephrine in minimizing COVID-19 severity: a review.|pdf=|usr=019}}
| |
| − | {{tp|p=33008774|t=2020. Dangers of scientific bias against herbal drugs for coronavirus disease 2019.|pdf=|usr=019}}
| |
| − | {{tp|p=32980768|t=2020. Impact of catch-up vaccination on aluminum exposure due to new laws and post social distancing.|pdf=|usr=019}}
| |
| − | {{tp|p=32983928|t=2020. The Application of Corticosteroids in COVID-19: A Two-edged Sword.|pdf=|usr=019}}
| |
| − | {{tp|p=32958009|t=2020. The use of mesenchymal stromal cells in the treatment of coronavirus disease 2019.|pdf=|usr=019}}
| |
| − | {{tp|p=32904944|t=2020. Vitamin D and immune regulation: antibacterial, antiviral, anti-inflammatory.|pdf=|usr=019}}
| |
| − | {{tp|p=32984792|t=2020. Artificial intelligence in COVID-19 drug repurposing.|pdf=|usr=019}}
| |
| − | {{tp|p=33015597|t=2020. Evaluating interest in off-label use of disinfectants for COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=33024252|t=2020. Antiviral activity of a novel mixture of natural antimicrobials, in vitro, and in a chicken infection model in vivo.|pdf=|usr=019}}
| |
| − | {{tp|p=33017762|t=2020. Chloroquine commonly induces hormetic dose responses.|pdf=|usr=019}}
| |
| − | {{tp|p=32876237|t=2020. Analisis preliminar in silico de azitromicina con proteinas humanas relacionadas al SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=32940187|t=2020. Tocilizumab in Sars-cov-2 Patients with the Syndrome of Cytokine Storm; a Narrative review.|pdf=|usr=019}}
| |
| − | {{tp|p=33020836|t=2020. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study.|pdf=|usr=019}}
| |
| − | {{tp|p=32892403|t=2020. Oromucosal immunomodulation as clinical spectrum mitigating factor in SARS-CoV-2 infection.|pdf=|usr=019}}
| |
| − | {{tp|p=32914670|t=2020. Biomarker-guided application of low-dose anakinra in an acute respiratory distress syndrome patient with severe COVID-19 and cytokine release syndrome.|pdf=|usr=019}}
| |
| − | {{tp|p=32907861|t=2020. De novo design of picomolar SARS-CoV-2 miniprotein inhibitors.|pdf=|usr=019}}
| |
| − |
| |
| − | {{tp|p=32984783|t=2020. Towards characterized convalescent plasma for COVID-19: The dose matters.|pdf=|usr=019}}
| |
| − | {{tp|p=32923991|t=2020. Compassionate use of convalescent plasma for treatment of moderate and severe pneumonia in COVID-19 patients and association with IgG antibody levels in donated plasma.|pdf=|usr=019}}
| |
| − | {{tp|p=33015938|t=2020. A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=32975484|t=2020. Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine.|pdf=|usr=019}}
| |
| − | {{tp|p=32897177|t=2020. SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates.|pdf=|usr=019}}
| |
| − | {{tp|p=32923016|t=2020. Efficacy and safety of triazavirin therapy for coronavirus disease 2019: A pilot randomized controlled trial.|pdf=|usr=019}}
| |
| − | {{tp|p=32953196|t=2020. Challenges in the development of a vaccine against COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32846177|t=2020. Biomedical application, drug delivery and metabolic pathway of antiviral nanotherapeutics for combating viral pandemic: A review.|pdf=|usr=019}}
| |
| − | {{tp|p=32835682|t=2020. Do nutrients and other bioactive molecules from foods have anything to say in the treatment against COVID-19?|pdf=|usr=019}}
| |
| − | {{tp|p=33003236|t=2020. Preprocedural Use of Povidone-Iodine Mouthwash during Dental Procedures in the COVID-19 Pandemic.|pdf=|usr=019}}
| |
| − | {{tp|p=32968954|t=2020. Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization.|pdf=|usr=019}}
| |
| − | {{tp|p=32912961|t=2020. Observational study on off-label use of tocilizumab in patients with severe COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32981802|t=2020. COVID-19 randomized controlled trials in medRxiv and PubMed.|pdf=|usr=019}}
| |
| − | {{tp|p=33010419|t=2020. Therapeutic Strategies for SARS-CoV-2 acting on ACE-2.|pdf=|usr=019}}
| |
| − | {{tp|p=32941927|t=2020. Corticosteroid therapy is associated with the delay of SARS-CoV-2 clearance in COVID-19 patients.|pdf=|usr=019}}
| |
| − | {{tp|p=33011243|t=2020. New putative insights into neprilysin (NEP)-dependent pharmacotherapeutic role of roflumilast in treating COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32931782|t=2020. Possibility of magnesium supplementation for supportive treatment in patients with COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32926918|t=2020. COVID-19 associated complications and potential therapeutic targets.|pdf=|usr=019}}
| |
| − | {{tp|p=32971089|t=2020. Integrative transcriptomics analysis of lung epithelial cells and identification of repurposable drug candidates for COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32949606|t=2020. Antiviral activity of chlorpromazine, fluphenazine, perphenazine, prochlorperazine, and thioridazine towards RNA-viruses. A review.|pdf=|usr=019}}
| |
| − | {{tp|p=32946870|t=2020. Can pentoxifylline and similar xanthine derivatives find a niche in COVID-19 therapeutic strategies? A ray of hope in the midst of the pandemic.|pdf=|usr=019}}
| |
| − | {{tp|p=32919938|t=2020. Macrophage responses associated with COVID-19: A pharmacological perspective.|pdf=|usr=019}}
| |
| − | {{tp|p=32943404|t=2020. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial.|pdf=|usr=019}}
| |
| − | {{tp|p=32983273|t=2020. Why physical activity matters for older adults in a time of pandemic.|pdf=|usr=019}}
| |
| − | {{tp|p=32963564|t=2020. Tea Polyphenols EGCG and Theaflavin Inhibit the Activity of SARS-CoV-2 3CL-Protease In Vitro.|pdf=|usr=019}}
| |
| − | {{tp|p=32963563|t=2020. Efficacy of Lianhua Qingwen Compared with Conventional Drugs in the Treatment of Common Pneumonia and COVID-19 Pneumonia: A Meta-Analysis.|pdf=|usr=019}}
| |
| − | {{tp|p=32901214|t=2020. Frontiers in the COVID-19 vaccines development.|pdf=|usr=019}}
| |
| − | {{tp|p=32934806|t=2020. Prediction of repurposed drugs for treating lung injury in COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32971210|t=2020. Comprehensive assessment of side effects in COVID-19 drug pipeline from a network perspective.|pdf=|usr=019}}
| |
| − | {{tp|p=32860861|t=2020. Synergistic effects of anionic surfactants on coronavirus (SARS-CoV-2) virucidal efficiency of sanitizing fluids to fight COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32822775|t=2020. Tocilizumab improves oxidative stress and endothelial glycocalyx: A mechanism that may explain the effects of biological treatment on COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32838301|t=2020. Employing bioactive compounds derived from Ipomoea obscura (L.) to evaluate potential inhibitor for SARS-CoV-2 main protease and ACE2 protein.|pdf=|usr=019}}
| |
| − | {{tp|p=32846611|t=2020. Potential contribution of beneficial microbes to face the COVID-19 pandemic.|pdf=|usr=019}}
| |
| − | {{tp|p=33011274|t=2020. Control of systemic inflammation through early nitric oxide supplementation with nitric oxide releasing nanoparticles.|pdf=|usr=019}}
| |
| − | {{tp|p=32974328|t=2020. Low-Cost, Large-Scale Production of the Anti-viral Lectin Griffithsin.|pdf=|usr=019}}
| |
| − | {{tp|p=32974295|t=2020. Potential Applications of Nanomaterials to Quench the Cytokine Storm in Coronavirus Disease 19.|pdf=|usr=019}}
| |
| − | {{tp|p=32850752|t=2020. Prospects for RNAi Therapy of COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32984339|t=2020. Repurposing Fragile X Drugs to Inhibit SARS-CoV-2 Viral Reproduction.|pdf=|usr=019}}
| |
| − | {{tp|p=33013911|t=2020. Scientific Rationale for a Bottom-Up Approach to Target the Host Response in Order to Try and Reduce the Numbers Presenting With Adult Respiratory Distress Syndrome Associated With COVID-19. Is There a Role for Statins and COX-2 Inhibitors in the Prevention and Early Treatment of the Disease?|pdf=|usr=019}}
| |
| − | {{tp|p=33013871|t=2020. Mitigating Coronavirus Induced Dysfunctional Immunity for At-Risk Populations in COVID-19: Trained Immunity, BCG and "New Old Friends".|pdf=|usr=019}}
| |
| − | {{tp|p=33013857|t=2020. Identification of Novel Candidate Epitopes on SARS-CoV-2 Proteins for South America: A Review of HLA Frequencies by Country.|pdf=|usr=019}}
| |
| − | {{tp|p=32983183|t=2020. What Would Jenner and Pasteur Have Done About COVID-19 Coronavirus? The Urges of a Vaccinologist.|pdf=|usr=019}}
| |
| − | {{tp|p=32983179|t=2020. Immune Modulation as a Therapeutic Option During the SARS-CoV-2 Outbreak: The Case for Antimalarial Aminoquinolines.|pdf=|usr=019}}
| |
| − | {{tp|p=32983123|t=2020. Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome.|pdf=|usr=019}}
| |
| − | {{tp|p=32973818|t=2020. PI3Kdelta Inhibition as a Potential Therapeutic Target in COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32973815|t=2020. Hyperinflammation and Fibrosis in Severe COVID-19 Patients: Galectin-3, a Target Molecule to Consider.|pdf=|usr=019}}
| |
| − | {{tp|p=32973814|t=2020. Immunomodulatory and Antiviral Activity of Metformin and Its Potential Implications in Treating Coronavirus Disease 2019 and Lung Injury.|pdf=|usr=019}}
| |
| − | {{tp|p=32973779|t=2020. The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development.|pdf=|usr=019}}
| |
| − | {{tp|p=32922409|t=2020. Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement, Contact Activation and Kallikrein-Kinin System.|pdf=|usr=019}}
| |
| − | {{tp|p=32922408|t=2020. Vaccine Development Against COVID-19 Prior to Pandemic Outbreaks, Using in vitro Evolution and Reverse Genetics.|pdf=|usr=019}}
| |
| − | {{tp|p=32903555|t=2020. Immunomodulatory Drugs in the Management of SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=32926320|t=2020. Chinese herbal medicine reduces mortality in patients with severe and critical Coronavirus disease 2019: a retrospective cohort study.|pdf=|usr=019}}
| |
| − | {{tp|p=32926319|t=2020. Clinical features and the traditional Chinese medicine therapeutic characteristics of 293 COVID-19 inpatient cases.|pdf=|usr=019}}
| |
| − | {{tp|p=32903552|t=2020. A Simple Bayesian Method for Evaluating Whether Data From Patients With Rheumatic Diseases Who Have Been Under Chronic Hydroxychloroquine Medication Since Before the COVID-19 Outbreak Can Speak to Hydroxychloroquine's Prophylactic Effect Against Infection With SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=32982999|t=2020. Severity of Coronavirus Disease 2019 (COVID-19): Does Surfactant Matter?|pdf=|usr=019}}
| |
| − | {{tp|p=32903349|t=2020. Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?|pdf=|usr=019}}
| |
| − | {{tp|p=33015130|t=2020. Selenium and RNA Virus Interactions: Potential Implications for SARS-CoV-2 Infection (COVID-19).|pdf=|usr=019}}
| |
| − | {{tp|p=32984400|t=2020. Understanding Selenium and Glutathione as Antiviral Factors in COVID-19: Does the Viral M(pro) Protease Target Host Selenoproteins and Glutathione Synthesis?|pdf=|usr=019}}
| |
| − | {{tp|p=33014780|t=2020. Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=32974166|t=2020. Commentary: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.|pdf=|usr=019}}
| |
| − | {{tp|p=32923397|t=2020. Management of Patients With Hematologic Malignancies During the COVID-19 Pandemic: Practical Considerations and Lessons to Be Learned.|pdf=|usr=019}}
| |
| − | {{tp|p=33013421|t=2020. Inhibiting Extracellular Vesicle Trafficking as Antiviral Approach to Corona Virus Disease 2019 Infection.|pdf=|usr=019}}
| |
| − | {{tp|p=33013412|t=2020. Efficacy and Safety of Corticosteroid Treatment in Patients With COVID-19: A Systematic Review and Meta-Analysis.|pdf=|usr=019}}
| |
| − | {{tp|p=33013397|t=2020. Clinical Studies on the Treatment of Novel Coronavirus Pneumonia With Traditional Chinese Medicine-A Literature Analysis.|pdf=|usr=019}}
| |
| − | {{tp|p=33013395|t=2020. Research Progress on Main Symptoms of Novel Coronavirus Pneumonia Improved by Traditional Chinese Medicine.|pdf=|usr=019}}
| |
| − | {{tp|p=33013375|t=2020. Montelukast Drug May Improve COVID-19 Prognosis: A Review of Evidence.|pdf=|usr=019}}
| |
| − | {{tp|p=32982751|t=2020. Coronavirus Disease 2019 Related Clinical Studies: A Cross-Sectional Analysis.|pdf=|usr=019}}
| |
| − | {{tp|p=32982743|t=2020. Immunosuppressive Drugs and COVID-19: A Review.|pdf=|usr=019}}
| |
| − | {{tp|p=32982720|t=2020. SARS-CoV-2 Treatment Approaches: Numerous Options, No Certainty for a Versatile Virus.|pdf=|usr=019}}
| |
| − | {{tp|p=32973537|t=2020. Does Lithium Deserve a Place in the Treatment Against COVID-19? A Preliminary Observational Study in Six Patients, Case Report.|pdf=|usr=019}}
| |
| − | {{tp|p=32973535|t=2020. Quality Assessment of the Chinese Clinical Trial Protocols Regarding Treatments for Coronavirus Disease 2019.|pdf=|usr=019}}
| |
| − | {{tp|p=32973527|t=2020. Harnessing Memory NK Cell to Protect Against COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=33015643|t=2020. Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial.|pdf=|usr=019}}
| |
| − | {{tp|p=33015642|t=2020. The opening salvo of anti-complement therapy against COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32964210|t=2020. Tocilizumab in COVID-19: finding the optimal route and dose - Authors' reply.|pdf=|usr=019}}
| |
| − | {{tp|p=32964209|t=2020. Tocilizumab in COVID-19: finding the optimal route and dose.|pdf=|usr=019}}
| |
| − | {{tp|p=32929415|t=2020. COVACTA trial raises questions about tocilizumab's benefit in COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=33024086|t=2020. Is smaller better? Vaccine targeting recombinant receptor-binding domain might hold the key for mass production of effective prophylactics to fight the COVID-19 pandemic.|pdf=|usr=019}}
| |
| − | {{tp|p=33024082|t=2020. The efficacy assessment of convalescent plasma therapy for COVID-19 patients: a multi-center case series.|pdf=|usr=019}}
| |
| − | {{tp|p=33024075|t=2020. Salvianolic acid C potently inhibits SARS-CoV-2 infection by blocking the formation of six-helix bundle core of spike protein.|pdf=|usr=019}}
| |
| − | {{tp|p=33024071|t=2020. SARS-CoV-2: the many pros of targeting PLpro.|pdf=|usr=019}}
| |
| − | {{tp|p=32989778|t=2020. Provision of COVID-19 Convalescent Plasma in a Resource-Constrained State.|pdf=|usr=019}}
| |
| − | {{tp|p=32978802|t=2020. Characterization of 100 sequential SARS-CoV-2 convalescent plasma donations.|pdf=|usr=019}}
| |
| − | {{tp|p=32989856|t=2020. Treatment of Immunocompromised COVID-19 patients with Convalescent Plasma.|pdf=|usr=019}}
| |
| − | {{tp|p=32980540|t=2020. Claims about the safety and efficacy of early treatment of COVID-19 with hydroxychloroquine and azithromycin must be supported by real evidence.|pdf=|usr=019}}
| |
| − | {{tp|p=32956851|t=2020. Dangers of the use of hydroxychloroquine and azithromycin combination in COVID-19 patients.|pdf=|usr=019}}
| |
| − | {{tp|p=32916297|t=2020. Antimalarial drugs inhibit the replication of SARS-CoV-2: An in vitro evaluation.|pdf=|usr=019}}
| |
| − | {{tp|p=32891724|t=2020. Histamine release theory and roles of antihistamine in the treatment of cytokines storm of COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=33023856|t=2020. The Complement C5a-C5aR1 GPCR Axis in COVID-19 Therapeutics.|pdf=|usr=019}}
| |
| − | {{tp|p=32959455|t=2020. Pregnancy and COVID-19: Pharmacologic Considerations.|pdf=|usr=019}}
| |
| − | {{tp|p=32996648|t=2020. Pregnancies recovered from SARS-CoV-2 infection in second or third trimester: obstetric evolution.|pdf=|usr=019}}
| |
| − | {{tp|p=32990149|t=2020. Correlation analysis of coagulation dysfunction and liver damage in patients with novel coronavirus pneumonia: a single-center, retrospective, observational study.|pdf=|usr=019}}
| |
| − | {{tp|p=33012602|t=2020. Ensemble forecast modeling for the design of COVID-19 vaccine efficacy trials.|pdf=|usr=019}}
| |
| − | {{tp|p=33022950|t=2020. Cold-Adapted Live Attenuated SARS-Cov-2 Vaccine Completely Protects Human ACE2 Transgenic Mice from SARS-Cov-2 Infection.|pdf=|usr=019}}
| |
| − | {{tp|p=33022917|t=2020. Influences on Attitudes Regarding Potential COVID-19 Vaccination in the United States.|pdf=|usr=019}}
| |
| − | {{tp|p=32933365|t=2020. Optimization of hydroxychloroquine dosing scheme based on COVID-19 patients' characteristics: a review of the literature and simulations.|pdf=|usr=019}}
| |
| − | {{tp|p=32792464|t=2020. Knowledge transfer for large-scale vaccine manufacturing.|pdf=|usr=019}}
| |
| − | {{tp|p=32942923|t=2020. A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32940386|t=2020. Therapeutic plasma exchange therapy support for critical COVID-19: A case report.|pdf=|usr=019}}
| |
| − | {{tp|p=32926660|t=2020. Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19).|pdf=|usr=019}}
| |
| − | {{tp|p=32919880|t=2020. A consideration of convalescent plasma and plasma derivatives in the care of Severely-ill patients with COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32994125|t=2020. Convalescent plasma to aid in recovery of COVID-19 pneumonia in a child with acute lymphoblastic leukemia.|pdf=|usr=019}}
| |
| − | {{tp|p=32935877|t=2020. Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program.|pdf=|usr=019}}
| |
| − | {{tp|p=32935872|t=2020. SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with nonsevere disease.|pdf=|usr=019}}
| |
| − | {{tp|p=32896672|t=2020. Can influenza vaccine modify COVID-19 clinical course?|pdf=|usr=019}}
| |
| − | {{tp|p=33012020|t=2020. COVID-19 vaccine research and development: ethical issues.|pdf=|usr=019}}
| |
| − | {{tp|p=32926494|t=2020. Maternal and Perinatal Outcomes of Pregnant Women with SARS-COV-2 infection.|pdf=|usr=019}}
| |
| − | {{tp|p=32980199|t=2020. Intention of nurses to accept coronavirus disease 2019 vaccination and change of intention to accept seasonal influenza vaccination during the coronavirus disease 2019 pandemic: A cross-sectional survey.|pdf=|usr=019}}
| |
| − | {{tp|p=32985963|t=2020. Coronavirus Disease 2019 Vaccine Development: An Overview.|pdf=|usr=019}}
| |
| − | {{tp|p=33012270|t=2020. Letter to the Editor: Toll-Like Receptor Antagonists as a Potential Therapeutic Strategy Against Cytokine Storm in COVID-19-Infected Patients.|pdf=|usr=019}}
| |
| − | {{tp|p=32914674|t=2020. Can intravenous oxytocin infusion counteract hyperinflammation in COVID-19 infected patients?|pdf=|usr=019}}
| |
| − | {{tp|p=32893565|t=2020. [Investigation of modulating effect of Qingfei Paidu Decoction on host metabolism and gut microbiome in rats].|pdf=|usr=019}}
| |
| − |
| |
| − | {{tp|p=32973505|t=2020. Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32973504|t=2020. The C-C Chemokine Receptor Type 4 Is an Immunomodulatory Target of Hydroxychloroquine.|pdf=|usr=019}}
| |
| − | {{tp|p=32903363|t=2020. Corticosteroid Use in the Treatment of COVID-19: A Multicenter Retrospective Study in Hunan, China.|pdf=|usr=019}}
| |
| − | {{tp|p=33013486|t=2020. A Preventive Role of Exercise Across the Coronavirus 2 (SARS-CoV-2) Pandemic.|pdf=|usr=019}}
| |
| − | {{tp|p=32983220|t=2020. Pandemics and Traditional Plant-Based Remedies. A Historical-Botanical Review in the Era of COVID19.|pdf=|usr=019}}
| |
| − | {{tp|p=32922431|t=2020. COVID-19 Therapy: Could a Chlorophyll Derivative Promote Cellular Accumulation of Zn(2+) Ions to Inhibit SARS-CoV-2 RNA Synthesis?|pdf=|usr=019}}
| |
| − | {{tp|p=33014983|t=2020. A Basic Review of the Preliminary Evidence That COVID-19 Risk and Severity Is Increased in Vitamin D Deficiency.|pdf=|usr=019}}
| |
| − | {{tp|p=32967965|t=2020. Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action.|pdf=|usr=019}}
| |
| − | {{tp|p=32999432|t=2020. Imatinib is not a potent anti-SARS-CoV-2 drug.|pdf=|usr=019}}
| |
| − | {{tp|p=32979360|t=2020. Mesenchymal stem cell therapies for COVID-19: Current status and mechanism of action.|pdf=|usr=019}}
| |
| − | {{tp|p=32956664|t=2020. Assessment of effective imidazole derivatives against SARS-CoV-2 main protease through computational approach.|pdf=|usr=019}}
| |
| − | {{tp|p=32926920|t=2020. New insights on possible vaccine development against SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=32952690|t=2020. Possible Nutritional Interventions in COVID 19.|pdf=|usr=019}}
| |
| − | {{tp|p=32978312|t=2020. Antiviral Drug Discovery To Address the COVID-19 Pandemic.|pdf=|usr=019}}
| |
| − | {{tp|p=32963010|t=2020. Reply to Ozdemir, "Measles-Mumps-Rubella Vaccine and COVID-19 Relationship".|pdf=|usr=019}}
| |
| − | {{tp|p=32963005|t=2020. Measles-Mumps-Rubella Vaccine and COVID-19 Relationship.|pdf=|usr=019}}
| |
| − | {{tp|p=32929317|t=2020. What are the drugs having potential against COVID-19?|pdf=|usr=019}}
| |
| − | {{tp|p=32959021|t=2020. Expanded mesenchymal stem cells: a novel therapeutic approach for SARS-CoV-2 pneumonia (COVID-19). Concepts regarding a first case in Spain.|pdf=|usr=019}}
| |
| − | {{tp|p=32953990|t=2020. Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir.|pdf=|usr=019}}
| |
| − | {{tp|p=32964205|t=2020. Serum Levels of Vitamin C and Vitamin D in a Cohort of Critically Ill COVID-19 Patients of a North American Community Hospital Intensive Care Unit in May 2020: A Pilot Study.|pdf=|usr=019}}
| |
| − | {{tp|p=33004713|t=2020. COVID-19 deaths can be reduced - simply and safely!|pdf=|usr=019}}
| |
| − | {{tp|p=33004712|t=2020. Rationale for ozone-therapy as an adjuvant therapy in COVID-19: a narrative review.|pdf=|usr=019}}
| |
| − | {{tp|p=32895599|t=2020. Favipiravir: A new and emerging antiviral option in COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=33010355|t=2020. Jaundice in a patient treated with Anakinra in a context of Covid-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32898996|t=2020. Convalescent plasma therapy in critically ill coronavirus disease 2019 patients with persistently positive nucleic acid test, case series report.|pdf=|usr=019}}
| |
| − | {{tp|p=32976855|t=2020. Commentary: Statins, COVID-19, and coronary artery disease: killing two birds with one stone.|pdf=|usr=019}}
| |
| − | {{tp|p=32950636|t=2020. Use of Nasoil(R) via intranasal to control the harmful effects of Covid-19.|pdf=|usr=019}}
| |
| − | {{tp|p=33011363|t=2020. Novel cyclohexanone compound as a potential ligand against SARS-CoV-2 main-protease.|pdf=|usr=019}}
| |
| − | {{tp|p=32899776|t=2020. Evaluation of Antiviral, Antibacterial and Antiproliferative Activities of the Endophytic Fungus Curvularia papendorfii, and Isolation of a New Polyhydroxyacid.|pdf=|usr=019}}
| |
| − | {{tp|p=32998451|t=2020. Renin Angiotensin System, COVID-19 and Male Fertility: Any Risk for Conceiving?|pdf=|usr=019}}
| |
| − | {{tp|p=32962760|t=2020. Successful recovery of COVID-19-associated recurrent diarrhea and gastrointestinal hemorrhage using convalescent plasma.|pdf=|usr=019}}
| |
| − | {{tp|p=33000616|t=2020. Can estrogens protect against COVID-19? The COVID-19 puzzling and gender medicine.|pdf=|usr=019}}
| |
| − | {{tp|p=32921819|t=2020. The Challenges of Vaccine Development against Betacoronaviruses: Antibody Dependent Enhancement and Sendai Virus as a Possible Vaccine Vector.|pdf=|usr=019}}
| |
| − | {{tp|p=32920757|t=2020. Role of melatonin in the treatment of COVID-19; as an adjuvant through cluster differentiation 147 (CD147).|pdf=|usr=019}}
| |
| − | {{tp|p=32997257|t=2020. A multimodal deep learning-based drug repurposing approach for treatment of COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32996011|t=2020. Identification of potential inhibitors of coronavirus hemagglutinin-esterase using molecular docking, molecular dynamics simulation and binding free energy calculation.|pdf=|usr=019}}
| |
| − | {{tp|p=32926254|t=2020. Synthesis of 3,3'-methylenebis(4-hydroxyquinolin-2(1H)-ones) of prospective anti-COVID-19 drugs.|pdf=|usr=019}}
| |
| − | {{tp|p=32993479|t=2020. Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: a case series.|pdf=|usr=019}}
| |
| − | {{tp|p=32897518|t=2020. Effects of Antimalarial Drugs on Neuroinflammation-Potential Use for Treatment of COVID-19-Related Neurologic Complications.|pdf=|usr=019}}
| |
| − | {{tp|p=32906733|t=2020. The New Coronavirus (SARS-CoV-2): A Comprehensive Review on Immunity and the Application of Bioinformatics and Molecular Modeling to the Discovery of Potential Anti-SARS-CoV-2 Agents.|pdf=|usr=019}}
| |
| − | {{tp|p=32992875|t=2020. Targeting Host Defense System and Rescuing Compromised Mitochondria to Increase Tolerance against Pathogens by Melatonin May Impact Outcome of Deadly Virus Infection Pertinent to COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32987757|t=2020. Peptides: Prospects for Use in the Treatment of COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32977525|t=2020. The Application of Porphyrins and Their Analogues for Inactivation of Viruses.|pdf=|usr=019}}
| |
| − | {{tp|p=32963099|t=2020. In Silico Structure-Based Repositioning of Approved Drugs for Spike Glycoprotein S2 Domain Fusion Peptide of SARS-CoV-2: Rationale from Molecular Dynamics and Binding Free Energy Calculations.|pdf=|usr=019}}
| |
| − | {{tp|p=32877576|t=2020. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.|pdf=|usr=019}}
| |
| − | {{tp|p=32895172|t=2020. [A systematic pharmacological investigation of pharmacologically active ingredients in Toujie Quwen granules for treatment of COVID-19].|pdf=|usr=019}}
| |
| − | {{tp|p=32963581|t=2020. Antiviral nanoagents: More attention and effort needed?|pdf=|usr=019}}
| |
| − | {{tp|p=32952596|t=2020. Nanoceria as a possible agent for the management of COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32922510|t=2020. Multivalent nanomedicines to treat COVID-19: A slow train coming.|pdf=|usr=019}}
| |
| − | {{tp|p=32904707|t=2020. Nanomedicine strategies to target coronavirus.|pdf=|usr=019}}
| |
| − | {{tp|p=32989315|t=2020. Whither COVID-19 vaccines?|pdf=|usr=019}}
| |
| − | {{tp|p=32887884|t=2020. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease.|pdf=|usr=019}}
| |
| − | {{tp|p=32887876|t=2020. An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction.|pdf=|usr=019}}
| |
| − | {{tp|p=32943628|t=2020. Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis.|pdf=|usr=019}}
| |
| − | {{tp|p=32913273|t=2020. Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain.|pdf=|usr=019}}
| |
| − | {{tp|p=32855413|t=2020. Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication.|pdf=|usr=019}}
| |
| − | {{tp|p=32887954|t=2020. Immunological considerations for COVID-19 vaccine strategies.|pdf=|usr=019}}
| |
| − | {{tp|p=32989290|t=2020. Keeping track of the SARS-CoV-2 vaccine pipeline.|pdf=|usr=019}}
| |
| − | {{tp|p=32901129|t=2020. Haemoperfusion should only be used for COVID-19 in the context of randomized trials.|pdf=|usr=019}}
| |
| − | {{tp|p=32892293|t=2020. Hydroxychloroquine use and progression or prognosis of COVID-19: a systematic review and meta-analysis.|pdf=|usr=019}}
| |
| − | {{tp|p=33001407|t=2020. Locking down the CGRP pathway during the COVID-19 pandemic lockdown: the PandeMig study.|pdf=|usr=019}}
| |
| − | {{tp|p=32922804|t=2020. Preliminary report of in vitro and in vivo effectiveness of dornase alfa on SARS-CoV-2 infection.|pdf=|usr=019}}
| |
| − | {{tp|p=32895614|t=2020. Statins-based prophylactic mouthwash and nasal spray may protect against coronavirus disease 2019.|pdf=|usr=019}}
| |
| − | {{tp|p=32960622|t=2020. Interaccion entre la edad y el deficit de vitamina D en la COVID-19 grave.|pdf=|usr=019}}
| |
| − | {{tp|p=32911778|t=2020. Current State of Evidence: Influence of Nutritional and Nutrigenetic Factors on Immunity in the COVID-19 Pandemic Framework.|pdf=|usr=019}}
| |
| − | {{tp|p=33003648|t=2020. Effective Immune Functions of Micronutrients against SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=32963672|t=2020. Expedited COVID-19 vaccine trials: a rat-race with challenges and ethical issues.|pdf=|usr=019}}
| |
| − | {{tp|p=32911671|t=2020. Control Measures for SARS-CoV-2: A Review on Light-Based Inactivation of Single-Stranded RNA Viruses.|pdf=|usr=019}}
| |
| − | {{tp|p=32999768|t=2020. Potential COVID-19 papain-like protease PL(pro) inhibitors: repurposing FDA-approved drugs.|pdf=|usr=019}}
| |
| − | {{tp|p=32998368|t=2020. Papain-Like Proteases as Coronaviral Drug Targets: Current Inhibitors, Opportunities, and Limitations.|pdf=|usr=019}}
| |
| − | {{tp|p=32977547|t=2020. Potential of Cell-Free Supernatant from Lactobacillus plantarum NIBR97, Including Novel Bacteriocins, as a Natural Alternative to Chemical Disinfectants.|pdf=|usr=019}}
| |
| − | {{tp|p=32967280|t=2020. Molecular Features of Non-Selective Small Molecule Antagonists of the Bradykinin Receptors.|pdf=|usr=019}}
| |
| − | {{tp|p=33007416|t=2020. Natural product derived phytochemicals in managing acute lung injury by multiple mechanisms.|pdf=|usr=019}}
| |
| − | {{tp|p=32930523|t=2020. Pharmacological hypothesis: TPC2 antagonist tetrandrine as a potential therapeutic agent for COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32910933|t=2020. Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=33011728|t=2020. SARS-CoV-2 and the Possible Role of Raf/MEK/ERK Pathway in Viral Survival: Is This a Potential Therapeutic Strategy for COVID-19?|pdf=|usr=019}}
| |
| − | {{tp|p=32994757|t=2020. Possible pharmaceutical applications can be developed from naturally occurring phenanthroindolizidine and phenanthroquinolizidine alkaloids.|pdf=|usr=019}}
| |
| − | {{tp|p=32982616|t=2020. Flavonoids: A complementary approach to conventional therapy of COVID-19?|pdf=|usr=019}}
| |
| − | {{tp|p=32978039|t=2020. Systems pharmacological study illustrates the immune regulation, anti-infection, anti-inflammation, and multi-organ protection mechanism of Qing-Fei-Pai-Du decoction in the treatment of COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32943302|t=2020. Identification of phytochemicals as potential therapeutic agents that binds to Nsp15 protein target of coronavirus (SARS-CoV-2) that are capable of inhibiting virus replication.|pdf=|usr=019}}
| |
| − | {{tp|p=32949888|t=2020. Network pharmacology analysis of the therapeutic mechanisms of the traditional Chinese herbal formula Lian Hua Qing Wen in Corona virus disease 2019 (COVID-19), gives fundamental support to the clinical use of LHQW.|pdf=|usr=019}}
| |
| − | {{tp|p=32920291|t=2020. Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV Spike pseudotyped virus.|pdf=|usr=019}}
| |
| − | {{tp|p=32948420|t=2020. Caffeic acid derivatives (CAFDs) as inhibitors of SARS-CoV-2: CAFDs-based functional foods as a potential alternative approach to combat COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32967179|t=2020. Plants-Derived Biomolecules as Potent Antiviral Phytomedicines: New Insights on Ethnobotanical Evidences against Coronaviruses.|pdf=|usr=019}}
| |
| − | {{tp|p=32941437|t=2020. Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project).|pdf=|usr=019}}
| |
| − | {{tp|p=33022015|t=2020. Biochemical screening for SARS-CoV-2 main protease inhibitors.|pdf=|usr=019}}
| |
| − | {{tp|p=33007039|t=2020. Brief Report: Hydroxychloroquine does not induce hemolytic anemia or organ damage in a "humanized" G6PD A- mouse model.|pdf=|usr=019}}
| |
| − | {{tp|p=33006999|t=2020. In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm.|pdf=|usr=019}}
| |
| − | {{tp|p=33002032|t=2020. In-silico design of a potential inhibitor of SARS-CoV-2 S protein.|pdf=|usr=019}}
| |
| − | {{tp|p=32976513|t=2020. Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection.|pdf=|usr=019}}
| |
| − | {{tp|p=32960899|t=2020. Second week methyl-prednisolone pulses improve prognosis in patients with severe coronavirus disease 2019 pneumonia: An observational comparative study using routine care data.|pdf=|usr=019}}
| |
| − | {{tp|p=32941512|t=2020. SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels.|pdf=|usr=019}}
| |
| − | {{tp|p=32915877|t=2020. Traditional Chinese medicine Lianhua Qingwen treating corona virus disease 2019(COVID-19): Meta-analysis of randomized controlled trials.|pdf=|usr=019}}
| |
| − | {{tp|p=32915876|t=2020. A new advanced in silico drug discovery method for novel coronavirus (SARS-CoV-2) with tensor decomposition-based unsupervised feature extraction.|pdf=|usr=019}}
| |
| − | {{tp|p=32913357|t=2020. Competing with a pandemic: Trends in research design in a time of Covid-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32903258|t=2020. Efficacy of corticosteroids in non-intensive care unit patients with COVID-19 pneumonia from the New York Metropolitan region.|pdf=|usr=019}}
| |
| − | {{tp|p=32983403|t=2020. Hydroxychloroquine and chloroquine for COVID-19: psychiatric aspects of patient safety considerations.|pdf=|usr=019}}
| |
| − | {{tp|p=33014364|t=2020. Convalescent Blood Products in COVID-19: A Narrative Review.|pdf=|usr=019}}
| |
| − | {{tp|p=32952617|t=2020. Oral disease-modifying antirheumatic drugs and immunosuppressants with antiviral potential, including SARS-CoV-2 infection: a review.|pdf=|usr=019}}
| |
| − | {{tp|p=32974002|t=2020. Clozapine prescribing in COVID-19 positive medical inpatients: a case series.|pdf=|usr=019}}
| |
| − | {{tp|p=32922212|t=2020. Thrombotic events following tocilizumab therapy in critically ill COVID-19 patients: a Facade for prognostic markers.|pdf=|usr=019}}
| |
| − | {{tp|p=32900176|t=2020. Pasient med alvorlig covid-19 behandlet med rekonvalesensplasma.|pdf=|usr=019}}
| |
| − | {{tp|p=32900168|t=2020. Pasient med alvorlig covid-19 behandlet med steroider.|pdf=|usr=019}}
| |
| − | {{tp|p=32998488|t=2020. Status for vaksineutvikling mot covid-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32920000|t=2020. Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach.|pdf=|usr=019}}
| |
| − | {{tp|p=32957454|t=2020. Novel Binding Mechanisms of Fusion Broad Range Anti-Infective Protein Ricin A Chain Mutant-Pokeweed Antiviral Protein 1 (RTAM-PAP1) against SARS-CoV-2 Key Proteins in Silico.|pdf=|usr=019}}
| |
| − | {{tp|p=32972861|t=2020. Promoting access to COVID-19 convalescent plasma in low- and middle-income countries.|pdf=|usr=019}}
| |
| − | {{tp|p=33011076|t=2020. Convalescent plasma therapy in patients with COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32933845|t=2020. Response Letter: Treatment for emerging viruses: Convalescent plasma and COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32900597|t=2020. Convalescent plasma as a treatment modality for coronavirus disease 2019 in Sudan.|pdf=|usr=019}}
| |
| − | {{tp|p=32669327|t=2020. A Novel Mucosal Adjuvant System for Immunization against Avian Coronavirus Causing Infectious Bronchitis.|pdf=|usr=019}}
| |
| − | {{tp|p=32913137|t=2020. Heparin-binding Peptides as Novel Therapies to Stop SARS-CoV-2 Cellular Entry and Infection.|pdf=|usr=019}}
| |
| − |
| |
| − | {{tp|p=32963442|t=2020. Past, Present, and Future of Remdesivir: An Overview of the Antiviral in Recent Times.|pdf=|usr=019}}
| |
| − | {{tp|p=32922463|t=2020. Thalidomide against Coronavirus Disease 2019 (COVID-19): A Medicine with a Thousand Faces.|pdf=|usr=019}}
| |
| − | {{tp|p=32947026|t=2020. Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma.|pdf=|usr=019}}
| |
| − | {{tp|p=32962355|t=2020. Assessment of proton-coupled conformational dynamics of SARS and MERS coronavirus papain-like proteases: Implication for designing broad-spectrum antiviral inhibitors.|pdf=|usr=019}}
| |
| − | {{tp|p=32920346|t=2020. Preanesthetic Povidone-Iodine gargles for patients with COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32910806|t=2020. Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor binding domain IgG correlate with virus neutralization.|pdf=|usr=019}}
| |
| − | {{tp|p=32976118|t=2020. Corticosteroids, COVID-19 pneumonia, and acute respiratory distress syndrome.|pdf=|usr=019}}
| |
| − | {{tp|p=32931482|t=2020. Drugs of unproven benefit for COVID-19: a pharma perspective on ethical allocation of available therapies.|pdf=|usr=019}}
| |
| − | {{tp|p=32967358|t=2020. Can Adenosine Fight COVID-19 Acute Respiratory Distress Syndrome?|pdf=|usr=019}}
| |
| − | {{tp|p=32937800|t=2020. Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32933039|t=2020. The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients.|pdf=|usr=019}}
| |
| − | {{tp|p=32932930|t=2020. Repurposing Immunomodulatory Therapies against Coronavirus Disease 2019 (COVID-19) in the Era of Cardiac Vigilance: A Systematic Review.|pdf=|usr=019}}
| |
| − | {{tp|p=32900588|t=2020. Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era?|pdf=|usr=019}}
| |
| − | {{tp|p=32905026|t=2020. Pharmaceutical assessment of polyvinylpyrrolidone (PVP): As excipient from conventional to controlled delivery systems with a spotlight on COVID-19 inhibition.|pdf=|usr=019}}
| |
| − | {{tp|p=32989715|t=2020. Expert Forecasts of COVID-19 Vaccine Development Timelines.|pdf=|usr=019}}
| |
| − | {{tp|p=32943741|t=2020. Promising effects of exercise on the cardiovascular, metabolic and immune system during COVID-19 period.|pdf=|usr=019}}
| |
| − | {{tp|p=32921965|t=2020. Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis.|pdf=|usr=019}}
| |
| − | {{tp|p=32920049|t=2020. Anti-Frameshifting Ligand Active against SARS Coronavirus-2 Is Resistant to Natural Mutations of the Frameshift-Stimulatory Pseudoknot.|pdf=|usr=019}}
| |
| − | {{tp|p=32891636|t=2020. MicroRNAs targeting the SARS-CoV-2 entry receptor ACE2 in cardiomyocytes.|pdf=|usr=019}}
| |
| − | {{tp|p=32952595|t=2020. Ramatroban as a Novel Immunotherapy for COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=33007575|t=2020. An in-silico evaluation of COVID-19 main protease with clinically approved drugs.|pdf=|usr=019}}
| |
| − | {{tp|p=32920239|t=2020. Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2-P3 alpha-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach.|pdf=|usr=019}}
| |
| − | {{tp|p=32965508|t=2020. Insights into the biased activity of dextromethorphan and haloperidol towards SARS-CoV-2 NSP6: in silico binding mechanistic analysis.|pdf=|usr=019}}
| |
| − | {{tp|p=32904625|t=2021. Exploration of inhibitory action of Azo imidazole derivatives against COVID-19 main protease (M(pro)): A computational study.|pdf=|usr=019}}
| |
| − | {{tp|p=32963413|t=2021. Synthesis, characterization and computational study on potential inhibitory action of novel azo imidazole derivatives against COVID-19 main protease (M(pro): 6LU7).|pdf=|usr=019}}
| |
| − | {{tp|p=32997331|t=2020. Treatment of COVID-19 atypical pneumonia by early Tocilizumab administration in "non-critically-ill" patients on hemodialysis.|pdf=|usr=019}}
| |
| − | {{tp|p=32996110|t=2020. COVID-19 and acute kidney injury in pediatric subjects: is there a place for eculizumab treatment?|pdf=|usr=019}}
| |
| − | {{tp|p=32981025|t=2020. Eculizumab treatment for renal failure in a pediatric patient with COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32908681|t=2020. Possible Retinal Impairment Secondary to Ritonavir Use in SARS-CoV-2 Patients: A Narrative Systematic Review.|pdf=|usr=019}}
| |
| − | {{tp|p=32944152|t=2020. Antiviral mouthwashes: possible benefit for COVID-19 with evidence-based approach.|pdf=|usr=019}}
| |
| − | {{tp|p=32744616|t=2020. Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2.|pdf=|usr=019}}
| |
| − | {{tp|p=32992693|t=2020. Pharmaconutrition in the Clinical Management of COVID-19: A Lack of Evidence-Based Research But Clues to Personalized Prescription.|pdf=|usr=019}}
| |
| − | {{tp|p=32923004|t=2020. Potential Treatment of Chinese and Western Medicine Targeting Nsp14 of SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=32968487|t=2020. The use of remdesivir outside of clinical trials during the COVID-19 pandemic.|pdf=|usr=019}}
| |
| − | {{tp|p=32891630|t=2020. Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing.|pdf=|usr=019}}
| |
| − | {{tp|p=32840378|t=2020. Alkamides and Piperamides as Potential Antivirals against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).|pdf=|usr=019}}
| |
| − | {{tp|p=32952005|t=2020. Coronavirus Disease 2019: Quick Diet and Nutrition Guide for Patients With Chronic Kidney Disease.|pdf=|usr=019}}
| |
| − | {{tp|p=32992538|t=2020. Nutritional Risk Screening Tools for Older Adults with COVID-19: A Systematic Review.|pdf=|usr=019}}
| |
| − | {{tp|p=32967126|t=2020. Immune Modulatory Effects of Vitamin D on Viral Infections.|pdf=|usr=019}}
| |
| − | {{tp|p=32932831|t=2020. Impact of Vitamin D Deficiency on COVID-19-A Prospective Analysis from the CovILD Registry.|pdf=|usr=019}}
| |
| − | {{tp|p=32927735|t=2020. Vitamin D Deficiency and Outcome of COVID-19 Patients.|pdf=|usr=019}}
| |
| − | {{tp|p=32942131|t=2020. Induction of ketosis as a potential therapeutic option to limit hyperglycemia and prevent cytokine storm in COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32911430|t=2020. Vitamin C as prophylaxis and adjunctive medical treatment for COVID-19?|pdf=|usr=019}}
| |
| − | {{tp|p=32917467|t=2020. Nutritional approach to patients with coronavirus: Our experience in a 914 COVID-19-bed hospital.|pdf=|usr=019}}
| |
| − | {{tp|p=32991984|t=2020. SARS-CoV-2 receptor ACE2 is expressed in human conjunctival tissue, especially in diseased conjunctival tissue.|pdf=|usr=019}}
| |
| − | {{tp|p=32923151|t=2020. Combination treatments with hydroxychloroquine and azithromycin are compatible with the therapeutic induction of anticancer immune responses.|pdf=|usr=019}}
| |
| − | {{tp|p=32898468|t=2020. Convalescent plasma therapy: a promising coronavirus disease 2019 treatment strategy.|pdf=|usr=019}}
| |
| − | {{tp|p=32934969|t=2020. Remdesivir Treatment for Severe COVID-19 in Third-Trimester Pregnancy: Case Report and Management Discussion.|pdf=|usr=019}}
| |
| − | {{tp|p=32938758|t=2020. Relationships between hyperinsulinaemia, magnesium, vitamin D, thrombosis and COVID-19: rationale for clinical management.|pdf=|usr=019}}
| |
| − | {{tp|p=32895293|t=2020. Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32901226|t=2020. Vitamin D and COVID-19: Is something better than nothing?|pdf=|usr=019}}
| |
| − | {{tp|p=33014275|t=2020. COVID-19: Proposing a Ketone-Based Metabolic Therapy as a Treatment to Blunt the Cytokine Storm.|pdf=|usr=019}}
| |
| − | {{tp|p=32855764|t=2020. Natural Antioxidants: A Review of Studies on Human and Animal Coronavirus.|pdf=|usr=019}}
| |
| − | {{tp|p=32942797|t=2020. Overview of Stem Cell Therapy for Acute Respiratory Distress Syndrome with Focus on COVID 19.|pdf=|usr=019}}
| |
| − | {{tp|p=32942796|t=2020. Safety and Effectiveness of Intravascular Mesenchymal Stem Cells to Treat Organ Failure and Possible Application in COVID-19 Complications.|pdf=|usr=019}}
| |
| − | {{tp|p=32942793|t=2020. COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine.|pdf=|usr=019}}
| |
| − | {{tp|p=32997719|t=2020. Translational Research in the Time of COVID-19-Dissolving Boundaries.|pdf=|usr=019}}
| |
| − | {{tp|p=32946517|t=2020. Exploring links between vitamin D deficiency and COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=33013180|t=2021. Topical review on nano-vaccinology: Biochemical promises and key challenges.|pdf=|usr=019}}
| |
| − | {{tp|p=32977289|t=2020. Leukotrienes, a potential target for Covid-19.|pdf=|usr=019}}
| |
| − | {{tp|p=33005274|t=2020. Effective treatment of severe acute pancreatitis and COVID-19 pneumonia with tocilizumab.|pdf=|usr=019}}
| |
| − | {{tp|p=32956989|t=2020. Serum 25-hydroxyvitamin D levels and psychological distress symptoms in patients with affective disorders during the COVID-19 pandemic.|pdf=|usr=019}}
| |
| − | {{tp|p=32901209|t=2020. Radiological and clinical improvement in a patient with COVID-19 pneumonia postconvalescent plasma transfusion: A case report.|pdf=|usr=019}}
| |
| − | {{tp|p=33007504|t=2020. Mitigation of the replication of SARS-CoV-2 by nitric oxide in vitro.|pdf=|usr=019}}
| |
| − | {{tp|p=32992282|t=2020. Selenium and selenoproteins in viral infection with potential relevance to COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32972871|t=2020. Clinical study of novel coronavirus pneumonia prevention by melatonin.|pdf=|usr=019}}
| |
| − | {{tp|p=32962929|t=2020. Melatonin: a fertility-friendly anti-coronavirus agent.|pdf=|usr=019}}
| |
| − | {{tp|p=32982538|t=2020. Off-Label Use of Chloroquine and Hydroxychloroquine for COVID-19 Treatment in Africa Against WHO Recommendation.|pdf=|usr=019}}
| |
| − | {{tp|p=32893160|t=2020. Outcome of early-stage combination treatment with favipiravir and methylprednisolone for severe COVID-19 pneumonia: A report of 11 cases.|pdf=|usr=019}}
| |
| − | {{tp|p=32995261|t=2020. Methylprednisolone pulse therapy: An alternative management of severe COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32965370|t=2020. Safety alert for hospital environments and health professional: chlorhexidine is ineffective for coronavirus.|pdf=|usr=019}}
| |
| − | {{tp|p=32965359|t=2020. The effects of favipiravir on hematological parameters of covid-19 patients.|pdf=|usr=019}}
| |
| − | {{tp|p=32965395|t=2020. Justificativa e delineamento do estudo "Tocilizumabe em pacientes com COVID-19 moderado a grave: estudo aberto, multicentrico, randomizado, controlado" (TOCIBRAS).|pdf=|usr=019}}
| |
| − | {{tp|p=32921873|t=2020. Utilidad y seguridad de la automonitorizacion electrocardiografica durante el tratamiento con hidroxicloroquina y azitromicina en pacientes con COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32963418|t=2020. Recomendacion de ejercicio fisico en casa en periodo de pandemia por COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32900514|t=2020. Uso de ozonoterapia rectal en paciente anciana con neumonia grave por COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32935536|t=2020. Inmunidad frente a SARS-CoV-2: caminando hacia la vacunacion.|pdf=|usr=019}}
| |
| − | {{tp|p=32965457|t=2020. Early public research funding response to COVID-19 pandemic in Brazil.|pdf=|usr=019}}
| |
| − | {{tp|p=32964179|t=2020. Safety of intravenous anakinra in COVID-19 with evidence of hyperinflammation, a case series.|pdf=|usr=019}}
| |
| − | {{tp|p=32904919|t=2020. Mesenchymal Stem Cell Therapy-Is the Vessel Half Full or Half Empty?|pdf=|usr=019}}
| |
| − | {{tp|p=32904846|t=2020. Knowledge about COVID-19 and beliefs about and use of herbal products during the COVID-19 pandemic: a cross-sectional study in Saudi Arabia.|pdf=|usr=019}}
| |
| − | {{tp|p=33020690|t=2020. Comparing the impact of Hydroxychloroquine based regimens and standard treatment on COVID-19 patient outcomes: A retrospective cohort study.|pdf=|usr=019}}
| |
| − | {{tp|p=32917717|t=2020. Molecular characterization of ebselen binding activity to SARS-CoV-2 main protease.|pdf=|usr=019}}
| |
| − | {{tp|p=32948512|t=2020. Antibody-like proteins that capture and neutralize SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=32937442|t=2020. COVID-19: Rescue by transcriptional inhibition.|pdf=|usr=019}}
| |
| − | {{tp|p=32923629|t=2020. Viruses harness YxxO motif to interact with host AP2M1 for replication: A vulnerable broad-spectrum antiviral target.|pdf=|usr=019}}
| |
| − | {{tp|p=32923613|t=2020. Mandated Bacillus Calmette-Guerin (BCG) vaccination predicts flattened curves for the spread of COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32938937|t=2020. Structural models of human ACE2 variants with SARS-CoV-2 Spike protein for structure-based drug design.|pdf=|usr=019}}
| |
| − | {{tp|p=32973171|t=2020. Sequence analysis of SARS-CoV-2 genome reveals features important for vaccine design.|pdf=|usr=019}}
| |
| − | {{tp|p=33004978|t=2020. Designing a multi-epitope peptide based vaccine against SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=33004837|t=2020. Antiviral activity of digoxin and ouabain against SARS-CoV-2 infection and its implication for COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32963884|t=2020. Computer-Aided Analysis of Multiple SARS-CoV-2 Therapeutic Targets: Identification of Potent Molecules from African Medicinal Plants.|pdf=|usr=019}}
| |
| − | {{tp|p=32963228|t=2020. Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=32934211|t=2020. Convalescent plasma therapy for COVID-19: a tried-and-true old strategy?|pdf=|usr=019}}
| |
| − | {{tp|p=33011739|t=2020. A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=32981460|t=2020. Discovery of Drug-Like Ligands for the Mac1 Domain of SARS-CoV-2 Nsp3.|pdf=|usr=019}}
| |
| − | {{tp|p=33015537|t=2020. Elderly as a High-risk Group during COVID-19 Pandemic: Effect of Circadian Misalignment, Sleep Dysregulation and Melatonin Administration.|pdf=|usr=019}}
| |
| − | {{tp|p=32954212|t=2020. Cytokine Hemoadsorption in the Management of a Pregnant Woman with COVID-19 Pneumonia: Case Report.|pdf=|usr=019}}
| |
| − | {{tp|p=32935079|t=2020. Role of Dupilumab in Approved Indications of COVID-19 Patient: an Efficacy-Based Nonsystematic Critical Analysis.|pdf=|usr=019}}
| |
| − | {{tp|p=32904710|t=2020. A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges.|pdf=|usr=019}}
| |
| − | {{tp|p=32864572|t=2020. Treatment Options Available for COVID-19 and an Analysis on Possible Role of Combination of rhACE2, Angiotensin (1-7) and Angiotensin (1-9) as Effective Therapeutic Measure.|pdf=|usr=019}}
| |
| − | {{tp|p=32950067|t=2020. Human Mesenchymal Stromal Cells Are Resistant to SARS-CoV-2 Infection under Steady-State, Inflammatory Conditions and in the Presence of SARS-CoV-2-Infected Cells.|pdf=|usr=019}}
| |
| − | {{tp|p=32948252|t=2020. The role of mesenchymal stromal cells in immune modulation of COVID-19: focus on cytokine storm.|pdf=|usr=019}}
| |
| − | {{tp|p=32895900|t=2020. Mesenchymal Stromal Cells in Viral Infections: Implications for COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32920752|t=2020. COVID-19 and its Therapeutics: Special Emphasis on Mesenchymal Stem Cells Based Therapy.|pdf=|usr=019}}
| |
| − | {{tp|p=33009982|t=2020. Cell-Based Therapy for Severe COVID-19 Patients: Clinical Trials and Cost-Utility.|pdf=|usr=019}}
| |
| − | {{tp|p=33014070|t=2020. The Potential Use of Mesenchymal Stem Cells and Their Derived Exosomes as Immunomodulatory Agents for COVID-19 Patients.|pdf=|usr=019}}
| |
| − | {{tp|p=32961040|t=2020. Viral pandemic preparedness: A pluripotent stem cell-based machine-learning platform for simulating SARS-CoV-2 infection to enable drug discovery and repurposing.|pdf=|usr=019}}
| |
| − | {{tp|p=32907757|t=2020. Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present alpha-gal epitopes.|pdf=|usr=019}}
| |
| − | {{tp|p=33010978|t=2020. Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.|pdf=|usr=019}}
| |
| − | {{tp|p=32907759|t=2020. The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines.|pdf=|usr=019}}
| |
| − | {{tp|p=32987794|t=2020. Possible Cross-Reactivity between SARS-CoV-2 Proteins, CRM197 and Proteins in Pneumococcal Vaccines May Protect Against Symptomatic SARS-CoV-2 Disease and Death.|pdf=|usr=019}}
| |
| − |
| |
| − | {{tp|p=33015628|t=2020. Computational Evaluation of the Inhibition Efficacies of HIV Antivirals on SARS-CoV-2 (COVID-19) Protease and Identification of 3D Pharmacophore and Hit Compounds.|pdf=|usr=019}}
| |
| − | {{tp|p=32982145|t=2020. COVID-19: the androgen hypothesis.|pdf=|usr=019}}
| |
| − | {{tp|p=32991573|t=2020. A 63-Year-Old Woman with SARS-CoV-2 Infection, Who Developed Severe COVID-19 Pneumonia and Was Supported with Convalescent Plasma Therapy.|pdf=|usr=019}}
| |
| − | {{tp|p=33009361|t=2020. A 63-Year-Old Woman with a History of Non-Hodgkin Lymphoma with Persistent SARS-CoV-2 Infection Who Was Seronegative and Treated with Convalescent Plasma.|pdf=|usr=019}}
| |
| − | {{tp|p=32955087|t=2020. Creation and maintenance of a table for assessment of evolving evidence for COVID-19-related treatments.|pdf=|usr=019}}
| |
| − | {{tp|p=33001237|t=2020. FX06-COVID: Verbesserung der Oxygenierung durch FX06 in Intensivpatienten mit schweren Verlaufen von COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32990812|t=2020. Vitamins as adjunctive treatment for coronavirus disease!|pdf=|usr=019}}
| |
| − | {{tp|p=32976026|t=2020. Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel.|pdf=|usr=019}}
| |
| − | {{tp|p=33017175|t=2020. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 1).|pdf=|usr=019}}
| |
| − | {{tp|p=33017170|t=2020. Remdesivir for Adults With COVID-19 : A Living Systematic Review for an American College of Physicians Practice Points.|pdf=|usr=019}}
| |
| − | {{tp|p=33012516|t=2020. Sevoflurane may not be a complete sigh of relief in COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32959913|t=2020. A PHARMACOLOGICAL FRAMEWORK FOR INTEGRATING TREATING THE HOST, REPURPOSING AND THE DAMAGE RESPONSE FRAMEWORK IN COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32936703|t=2020. Nutritional management of patients during and after COVID-19 illness.|pdf=|usr=019}}
| |
| − | {{tp|p=32988425|t=2020. Invited Letter to Editor in response to: Finland's handling of selenium is a model in these times of coronavirus infections.|pdf=|usr=019}}
| |
| − | {{tp|p=32988420|t=2020. Finland's handling of selenium is a model in these times of coronavirus infections.|pdf=|usr=019}}
| |
| − | {{tp|p=32942296|t=2020. Potential inhibitors for the novel coronavirus (SARS-CoV-2).|pdf=|usr=019}}
| |
| − | {{tp|p=33003194|t=2020. Adverse events associated with potential drugs for COVID-19: a case study from real-world data.|pdf=|usr=019}}
| |
| − | {{tp|p=32985700|t=2020. Mining the past to treat the present, ever mindful of the future: Low-dose radiotherapy and COVID-19 pneumonia.|pdf=|usr=019}}
| |
| − | {{tp|p=32945149|t=2020. Convalescent Plasma for the Treatment of Severe COVID-19 Infection in Cancer Patients.|pdf=|usr=019}}
| |
| − | {{tp|p=32905553|t=2020. Towards COVID-19 Prophylaxis: An AIDS Preclinical Research Perspective.|pdf=|usr=019}}
| |
| − | {{tp|p=32923657|t=2020. Cannabidiol Modulates Cytokine Storm in Acute Respiratory Distress Syndrome Induced by Simulated Viral Infection Using Synthetic RNA.|pdf=|usr=019}}
| |
| − | {{tp|p=32918656|t=2020. Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug Interactions with Cardioactive Medications.|pdf=|usr=019}}
| |
| − | {{tp|p=32795413|t=2020. A Thermostable mRNA Vaccine against COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32970990|t=2020. Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy.|pdf=|usr=019}}
| |
| − | {{tp|p=32941803|t=2020. High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models.|pdf=|usr=019}}
| |
| − | {{tp|p=32941801|t=2020. Activate: Randomized Clinical Trial of BCG Vaccination against Infection in the Elderly.|pdf=|usr=019}}
| |
| − | {{tp|p=32931734|t=2020. A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=32992409|t=2020. SARS-COV-2 (COVID-19): Cellular and biochemical properties and pharmacological insights into new therapeutic developments.|pdf=|usr=019}}
| |
| − | {{tp|p=32803762|t=2020. Potential small-molecule drugs as available weapons to fight novel coronavirus (2019-nCoV): A review.|pdf=|usr=019}}
| |
| − | {{tp|p=32814759|t=2020. On-target versus off-target effects of drugs inhibiting the replication of SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=32934821|t=2020. Decreased HD-MIR2911 absorption in human subjects with the SIDT1 polymorphism fails to inhibit SARS-CoV-2 replication.|pdf=|usr=019}}
| |
| − | {{tp|p=32901211|t=2020. Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement.|pdf=|usr=019}}
| |
| − | {{tp|p=32802404|t=2020. Absorbed plant MIR2911 in honeysuckle decoction inhibits SARS-CoV-2 replication and accelerates the negative conversion of infected patients.|pdf=|usr=019}}
| |
| − | {{tp|p=32910920|t=2020. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike.|pdf=|usr=019}}
| |
| − | {{tp|p=32910919|t=2020. Snatching the Crown from SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=32798445|t=2020. Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice.|pdf=|usr=019}}
| |
| − | {{tp|p=32798444|t=2020. Approaches and Challenges in SARS-CoV-2 Vaccine Development.|pdf=|usr=019}}
| |
| − | {{tp|p=32941797|t=2020. Shining Light on the COVID-19 Pandemic: A Vitamin D Receptor Checkpoint in Defense of Unregulated Wound Healing.|pdf=|usr=019}}
| |
| − | {{tp|p=32868909|t=2020. New insights into the cell- and tissue-specificity of glucocorticoid actions.|pdf=|usr=019}}
| |
| − | {{tp|p=32830930|t=2020. Emergence, Transmission, and Potential Therapeutic Targets for the COVID-19 Pandemic Associated with the SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=33007239|t=2020. Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects.|pdf=|usr=019}}
| |
| − | {{tp|p=32984856|t=2020. Programming Multifaceted Pulmonary T Cell Immunity by Combination Adjuvants.|pdf=|usr=019}}
| |
| − | {{tp|p=32811977|t=2020. 25-Hydroxycholesterol is a potent SARS-CoV-2 inhibitor.|pdf=|usr=019}}
| |
| − | {{tp|p=32841042|t=2020. The Disillusioned Comfort with COVID-19 and the Potential of Convalescent Plasma and Cell Therapy.|pdf=|usr=019}}
| |
| − | {{tp|p=32830527|t=2020. Immunomodulation and Regeneration Properties of Dental Pulp Stem Cells: A Potential Therapy to Treat Coronavirus Disease 2019.|pdf=|usr=019}}
| |
| − | {{tp|p=32899484|t=2020. Hybrid Biopolymer and Lipid Nanoparticles with Improved Transfection Efficacy for mRNA.|pdf=|usr=019}}
| |
| − | {{tp|p=32887260|t=2020. Rationale for the Use of Radiation-Activated Mesenchymal Stromal/Stem Cells in Acute Respiratory Distress Syndrome.|pdf=|usr=019}}
| |
| − | {{tp|p=32942671|t=2020. Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?|pdf=|usr=019}}
| |
| − | {{tp|p=32854430|t=2020. Targeting the sAC-Dependent cAMP Pool to Prevent SARS-Cov-2 Infection.|pdf=|usr=019}}
| |
| − | {{tp|p=32847034|t=2020. Autophagy Augmentation to Alleviate Immune Response Dysfunction, and Resolve Respiratory and COVID-19 Exacerbations.|pdf=|usr=019}}
| |
| − | {{tp|p=32796683|t=2020. Small Molecule Inhibitors in the Treatment of Rheumatoid Arthritis and Beyond: Latest Updates and Potential Strategy for Fighting COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32834643|t=2020. Target specific mining of COVID-19 scholarly articles using one-class approach.|pdf=|usr=019}}
| |
| − | {{tp|p=31436895|t=2019. Characteristics of flavonoids as potent MERS-CoV 3C-like protease inhibitors.|pdf=|usr=019}}
| |
| − | {{tp|p=32836314|t=2020. Favipiravir - a Modern Antiviral Drug: Synthesis and Modifications.|pdf=|usr=019}}
| |
| − | {{tp|p=32834063|t=2020. Quantum mechanical simulation of Chloroquine drug interaction with C60 fullerene for treatment of COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32835090|t=2020. In Silico Identification of Potential Inhibitors of ADP-Ribose Phosphatase of SARS-CoV-2 nsP3 by Combining E-Pharmacophore- and Receptor-Based Virtual Screening of Database.|pdf=|usr=019}}
| |
| − | {{tp|p=32929323|t=2020. Rudolf Bauer: China anti-COVID-19 success is closely related with the role TCM played.|pdf=|usr=019}}
| |
| − | {{tp|p=32994803|t=2020. Applications, phytochemistry, pharmacological effects, pharmacokinetics, toxicity of Scutellaria baicalensis Georgi. and its probably potential therapeutic effects on COVID-19: a review.|pdf=|usr=019}}
| |
| − | {{tp|p=32905189|t=2020. Reflections on treatment of COVID-19 with traditional Chinese medicine.|pdf=|usr=019}}
| |
| − | {{tp|p=32863397|t=2020. Stability Indicating LC Method Development for Hydroxychloroquine Sulfate Impurities as Available for Treatment of COVID-19 and Evaluation of Risk Assessment Prior to Method Validation by Quality by Design Approach.|pdf=|usr=019}}
| |
| − | {{tp|p=32876256|t=2020. Terapia medicamentosa para infeccoes por coronavirus em humanos: revisao sistematica rapida.|pdf=|usr=019}}
| |
| − | {{tp|p=32830894|t=2020. Canakinumab to reduce deterioration of cardiac and respiratory function in SARS-CoV-2 associated myocardial injury with heightened inflammation (canakinumab in Covid-19 cardiac injury: The three C study).|pdf=|usr=019}}
| |
| − | {{tp|p=32941626|t=2020. No SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected Before the 2020 Pandemic.|pdf=|usr=019}}
| |
| − | {{tp|p=32990950|t=2020. Vitamin D status may indeed be a prognosticator for morbidity and mortality in patients with COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32975843|t=2020. Inactivation of SARS-CoV-2 and HCoV-229E in vitro by ColdZyme(R) a medical device mouth spray against the common cold.|pdf=|usr=019}}
| |
| − | {{tp|p=32965715|t=2020. Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: A preliminary report.|pdf=|usr=019}}
| |
| − | {{tp|p=32965677|t=2020. N-terminally truncated nucleocapsid protein of SARS-CoV-2 as a better serological marker than whole nucleocapsid protein in evaluating the immunogenicity of inactivated SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=32949157|t=2020. Safety of nontumor necrosis factor-targeted biologics in the COVID-19 pandemic.|pdf=|usr=019}}
| |
| − | {{tp|p=33022569|t=2020. Prediction of potential inhibitors of the dimeric SARS-CoV2 main proteinase through the MM/GBSA approach.|pdf=|usr=019}}
| |
| − | {{tp|p=33006287|t=2020. A Novel Strategy for the Development of Vaccines for SARS-CoV-2 (COVID-19) and Other Viruses Using AI and Viral Shell Disorder.|pdf=|usr=019}}
| |
| − | {{tp|p=32960061|t=2020. Theoretical Insights into the Anti-SARS-CoV-2 Activity of Chloroquine and Its Analogs and In Silico Screening of Main Protease Inhibitors.|pdf=|usr=019}}
| |
| − | {{tp|p=32957788|t=2020. Techniques and Strategies for Potential Protein Target Discovery and Active Pharmaceutical Molecule Screening in a Pandemic.|pdf=|usr=019}}
| |
| − | {{tp|p=32931291|t=2020. Generation of SARS-CoV-2 S1 Spike Glycoprotein Putative Antigenic Epitopes in Vitro by Intracellular Aminopeptidases.|pdf=|usr=019}}
| |
| − | {{tp|p=32914632|t=2020. Computational Immune Proteomics Approach to Target COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32907334|t=2020. Repurposing of FDA-Approved Toremifene to Treat COVID-19 by Blocking the Spike Glycoprotein and NSP14 of SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=32893632|t=2020. In Silico Drug Repurposing for SARS-CoV-2 Main Proteinase and Spike Proteins.|pdf=|usr=019}}
| |
| − | {{tp|p=32786890|t=2020. Interaction of Drug Candidates with Various SARS-CoV-2 Receptors: An in Silico Study to Combat COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32891161|t=2020. How to deal with a temporary suspension and restarting your trial: our experiences and lessons learnt.|pdf=|usr=019}}
| |
| − | {{tp|p=32993804|t=2020. Moving fast but going slow: coordination challenges for trials of COVID-19 post-exposure prophylaxis.|pdf=|usr=019}}
| |
| − | {{tp|p=32928313|t=2020. A quadruple blind, randomised controlled trial of gargling agents in reducing intraoral viral load among hospitalised COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial.|pdf=|usr=019}}
| |
| − | {{tp|p=32917258|t=2020. It is unprecedented: trial management during the COVID-19 pandemic and beyond.|pdf=|usr=019}}
| |
| − | {{tp|p=32988811|t=2020. Convalescent Plasma Rescued a Severe COVID-19 Patient with Chronic Myeloid Leukemia Blast Crisis and Myelofibrosis.|pdf=|usr=019}}
| |
| − | {{tp|p=32950044|t=2020. Efficacy of convalescent plasma according to blood groups in COVID-19 patients.|pdf=|usr=019}}
| |
| − | {{tp|p=32918809|t=2020. Paul G. Harch, MD: Hyperbaric Oxygen Therapy and Coronavirus Application.|pdf=|usr=019}}
| |
| − | {{tp|p=32918807|t=2020. Vitamin D: A Nutrient To Bring To Light During COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32907358|t=2020. Traditional Chinese Medicine as Potential Therapy for COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=33017527|t=2020. Use of povidone as a mouthrinse to decrease the viral load of Covid-19 before dental care: Review of the literature.|pdf=|usr=019}}
| |
| − | {{tp|p=32918336|t=2020. Janus Family kinase (JAK) inhibitors in HLH and severe COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32929975|t=2020. Safety and Utility of Chloroquine/ Hydroxychloroquine in Palliative Care Patients.|pdf=|usr=019}}
| |
| − | {{tp|p=32560964|t=2020. Facts, not Fear: Safety of Hydroxychloroquine.|pdf=|usr=019}}
| |
| − | {{tp|p=32964535|t=2020. Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports.|pdf=|usr=019}}
| |
| − | {{tp|p=32921328|t=2020. Probiotics and COVID-19: Think about the link.|pdf=|usr=019}}
| |
| − | {{tp|p=32990020|t=2020. Flavonoids as a potential adjuvant therapy of COVID-19?|pdf=|usr=019}}
| |
| − | {{tp|p=32990019|t=2020. Could boron be used as coronavirus inactivation agent?|pdf=|usr=019}}
| |
| − | {{tp|p=32955901|t=2020. How do arbidol and its analogs inhibit the SARS-CoV-2?|pdf=|usr=019}}
| |
| − | {{tp|p=32986274|t=2020. Low-dose whole-lung radiation for COVID-19 pneumonia: Planned day 7 interim analysis of a registered clinical trial.|pdf=|usr=019}}
| |
| − | {{tp|p=32948613|t=2020. Repurposing Cancer Drugs for COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32941264|t=2020. The Use of Non-Steroidal Anti-inflammatory Drugs for Coronavirus Disease 2019: Adjunct Therapy.|pdf=|usr=019}}
| |
| − | {{tp|p=33017365|t=2020. Use of Nonsteroidal Anti-inflammatory Drugs for COVID-19 Infection: Adjunct Therapy?|pdf=|usr=019}}
| |
| − | {{tp|p=32990980|t=2020. The possible double-edged sword effects of vitamin D on COVID-19: A hypothesis.|pdf=|usr=019}}
| |
| − | {{tp|p=32997483|t=2020. Use of chloroquine or hydroxychloroquine in treatment of COVID-19: is it ethical?|pdf=|usr=019}}
| |
| − | {{tp|p=32984999|t=2020. Virtual screening for functional foods against the main protease of SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=32930657|t=2020. Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients.|pdf=|usr=019}}
| |
| − | {{tp|p=32897543|t=2020. Analysis of the prophylactic effect of thymosin drugs on COVID-19 for 435 medical staff: A hospital-based retrospective study.|pdf=|usr=019}}
| |
| − | {{tp|p=32897539|t=2020. Potential role of subcutaneous tocilizumab injections in patients with COVID-19 associated pneumonia.|pdf=|usr=019}}
| |
| − | {{tp|p=32940918|t=2020. Potential interventions for SARS-CoV-2 infections: Zinc showing promise.|pdf=|usr=019}}
| |
| − | {{tp|p=32936465|t=2020. Research progress and challenges to coronavirus vaccine development.|pdf=|usr=019}}
| |
| − | {{tp|p=32926453|t=2020. Methotrexate inhibits SARS-CoV-2 virus replication "in vitro".|pdf=|usr=019}}
| |
| − | {{tp|p=32918755|t=2020. Efficacy of tocilizumab in COVID-19: A systematic review and meta-analysis.|pdf=|usr=019}}
| |
| − | {{tp|p=33026649|t=2020. Suppression of SARS-CoV-2 infection in ex-vivo human lung tissues by targeting class III phosphoinositide 3-kinase.|pdf=|usr=019}}
| |
| − | {{tp|p=32794723|t=2020. Biological Rationale for the Repurposing of BCG Vaccine against SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=32786685|t=2020. Molecular Binding Mechanism and Pharmacology Comparative Analysis of Noscapine for Repurposing against SARS-CoV-2 Protease.|pdf=|usr=019}}
| |
| − |
| |
| − | {{tp|p=32944838|t=2020. Pulmonary administration of remdesivir in the treatment of COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32966040|t=2020. Targeting Polyamines Inhibits Coronavirus Infection by Reducing Cellular Attachment and Entry.|pdf=|usr=019}}
| |
| − | {{tp|p=32968208|t=2020. Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives.|pdf=|usr=019}}
| |
| − | {{tp|p=33005428|t=2020. Late i.v. steroid treatment for severe COVID-19-induced acute respiratory distress syndrome: a case report.|pdf=|usr=019}}
| |
| − | {{tp|p=32975565|t=2020. Coronavirus Disease 2019 (COVID-19) and Nutritional Status: The Missing Link?|pdf=|usr=019}}
| |
| − | {{tp|p=32955676|t=2020. Vitamin D status and COVID-19 in older adults.|pdf=|usr=019}}
| |
| − | {{tp|p=33014532|t=2020. Research progress on Mesenchymal Stem Cells (MSCs), Adipose-Derived Mesenchymal Stem Cells (AD-MSCs), Drugs, and Vaccines in Inhibiting COVID-19 Disease.|pdf=|usr=019}}
| |
| − | {{tp|p=33014531|t=2020. Stem Cell Based Therapy Option in COVID-19: Is It Really Promising?|pdf=|usr=019}}
| |
| − | {{tp|p=32905393|t=2020. Structural basis of SARS-CoV-2 main protease inhibition by a broad-spectrum anti-coronaviral drug.|pdf=|usr=019}}
| |
| − | {{tp|p=32991850|t=2020. Statin Treatment of COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32891399|t=2020. Meta-analysis of Effect of Statins in Patients with COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32835721|t=2020. Hydroxychloroquine at usual doses as an option for coronavirus disease 2019 treatment.|pdf=|usr=019}}
| |
| − | {{tp|p=32996774|t=2020. VITAMIN D SUPPLEMENTATION AS A RATIONAL PHARMACOLOGICAL APPROACH IN THE COVID-19 PANDEMIC.|pdf=|usr=019}}
| |
| − | {{tp|p=32897730|t=2020. Complement Inhibition with the C5 Blocker LFG316 in Severe COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32804682|t=2020. Vitamin D Supplementation in COVID-19 Patients: A Clinical Case Series.|pdf=|usr=019}}
| |
| − | {{tp|p=32946668|t=2020. Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched cohort study.|pdf=|usr=019}}
| |
| − | {{tp|p=32828137|t=2020. Accelerating Clinical Evaluation of Repurposed Combination Therapies for COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32828135|t=2020. Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study.|pdf=|usr=019}}
| |
| − | {{tp|p=32895612|t=2020. An overview of current COVID-19 clinical trials and ethical considerations editorial.|pdf=|usr=019}}
| |
| − | {{tp|p=32959507|t=2020. Association between trace levels of lithium in drinking water and COVID-19-associated mortality.|pdf=|usr=019}}
| |
| − | {{tp|p=33012858|t=2020. Melanie Saville: the end-to-end process needed for a SARS-CoV-2 vaccine.|pdf=|usr=019}}
| |
| − | {{tp|p=33017034|t=2020. Integrative Medicine Demonstrates Advantage in COVID-19 Treatment.|pdf=|usr=019}}
| |
| − | {{tp|p=33017033|t=2020. A Potential Chinese Medicine Granule Suppressing ARDS of COVID-19: Keguan-1.|pdf=|usr=019}}
| |
| − | {{tp|p=32974949|t=2020. Shedding light on the myths of ultraviolet radiation in the COVID-19 pandemic.|pdf=|usr=019}}
| |
| − | {{tp|p=32976637|t=2020. Covid-19: From structure to therapeutic targeting in studying approved drugs and local DNA vaccination.|pdf=|usr=019}}
| |
| − | {{tp|p=32986807|t=2020. Remdesivir failure with SARS-CoV-2 RNA-dependent RNA-polymerase mutation in a B-cell immunodeficient patient with protracted Covid-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32964918|t=2020. Double-blind, randomized, placebo-controlled trial with N-acetylcysteine for treatment of severe acute respiratory syndrome caused by COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32964913|t=2020. Decreased mortality in COVID-19 patients treated with Tocilizumab: a rapid systematic review and meta-analysis of observational studies.|pdf=|usr=019}}
| |
| − | {{tp|p=32955081|t=2020. Treatment of COVID-19 Patients with Prolonged Post-Symptomatic Viral Shedding with Leflunomide -- a Single-Center, Randomized, Controlled Clinical Trial.|pdf=|usr=019}}
| |
| − | {{tp|p=32948881|t=2020. Corticosteroid-related in-hospital hyperglycemia: does it negate mortality benefits in COVID-19?|pdf=|usr=019}}
| |
| − | {{tp|p=32934054|t=2020. Vitamin D binding protein in COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32907512|t=2020. SARS-CoV M(pro) inhibitory activity of aromatic disulfide compounds: QSAR model.|pdf=|usr=019}}
| |
| − | {{tp|p=32897178|t=2020. Molecular docking, validation, dynamics simulations, and pharmacokinetic prediction of natural compounds against the SARS-CoV-2 main-protease.|pdf=|usr=019}}
| |
| − | {{tp|p=32897173|t=2020. Drug similarity and structure-based screening of medicinal compounds to target macrodomain-I from SARS-CoV-2 to rescue the host immune system: a molecular dynamics study.|pdf=|usr=019}}
| |
| − | {{tp|p=32897138|t=2020. Screening of plant-based natural compounds as a potential COVID-19 main protease inhibitor: an in silico docking and molecular dynamics simulation approach.|pdf=|usr=019}}
| |
| − | {{tp|p=32896226|t=2020. In-silico screening of plant-derived antivirals against main protease, 3CL(pro) and endoribonuclease, NSP15 proteins of SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=32981461|t=2020. Pharmacophore based virtual screening, molecular docking, molecular dynamics and MM-GBSA approach for identification of prospective SARS-CoV-2 inhibitor from natural product databases.|pdf=|usr=019}}
| |
| − | {{tp|p=32969333|t=2020. Repurposing of the approved small molecule drugs in order to inhibit SARS-CoV-2 S protein and human ACE2 interaction through virtual screening approaches.|pdf=|usr=019}}
| |
| − | {{tp|p=32964805|t=2020. Repurposing drugs for treatment of SARS-CoV-2 infection: computational design insights into mechanisms of action.|pdf=|usr=019}}
| |
| − | {{tp|p=32964802|t=2020. Identification of destabilizing SNPs in SARS-CoV2-ACE2 protein and spike glycoprotein: implications for virus entry mechanisms.|pdf=|usr=019}}
| |
| − | {{tp|p=32960159|t=2020. The potential role of procyanidin as a therapeutic agent against SARS-CoV-2: a text mining, molecular docking and molecular dynamics simulation approach.|pdf=|usr=019}}
| |
| − | {{tp|p=32954984|t=2020. In silico modeling for quick prediction of inhibitory activity against 3CL(pro) enzyme in SARS CoV diseases.|pdf=|usr=019}}
| |
| − | {{tp|p=32948116|t=2020. Identification of potential inhibitors of SARS-CoV-2 main protease and spike receptor from 10 important spices through structure-based virtual screening and molecular dynamic study.|pdf=|usr=019}}
| |
| − | {{tp|p=32948103|t=2020. A computational approach to drug repurposing against SARS-CoV-2 RNA dependent RNA polymerase (RdRp).|pdf=|usr=019}}
| |
| − | {{tp|p=32940134|t=2020. A dynamic simulation study of FDA drug from zinc database against COVID-19 main protease receptor.|pdf=|usr=019}}
| |
| − | {{tp|p=32938313|t=2020. In silico investigation of spice molecules as potent inhibitor of SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=32936048|t=2020. Molecular basis of the potential interaction of SARS-CoV-2 spike protein to CD147 in COVID-19 associated-lymphopenia.|pdf=|usr=019}}
| |
| − | {{tp|p=32933378|t=2020. Targeting SARS-CoV-2 Nsp12/Nsp8 interaction interface with approved and investigational drugs: an in silico structure-based approach.|pdf=|usr=019}}
| |
| − | {{tp|p=32930058|t=2020. Naltrexone a potential therapeutic candidate for COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32930050|t=2020. Binding of raloxifene to human complement fragment 5a ((h)C5a): a perspective on cytokine storm and COVID19.|pdf=|usr=019}}
| |
| − | {{tp|p=32924827|t=2020. Potential protease inhibitors and their combinations to block SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=32924825|t=2020. Computational insight of dexamethasone against potential targets of SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=32909528|t=2020. Virtual screening of approved clinic drugs with main protease (3CL(pro)) reveals potential inhibitory effects on SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=33016237|t=2020. Structural analysis, virtual screening and molecular simulation to identify potential inhibitors targeting 2'-O-ribose methyltransferase of SARS-CoV-2 coronavirus.|pdf=|usr=019}}
| |
| − | {{tp|p=32959892|t=2020. Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment.|pdf=|usr=019}}
| |
| − | {{tp|p=32981089|t=2020. Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing.|pdf=|usr=019}}
| |
| − | {{tp|p=32998618|t=2020. The inhibitory effect of some natural bioactive compounds against SARS-CoV-2 main protease: insights from molecular docking analysis and molecular dynamic simulation.|pdf=|usr=019}}
| |
| − | {{tp|p=32977363|t=2020. Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men.|pdf=|usr=019}}
| |
| − | {{tp|p=32907596|t=2020. In vitro virucidal activity of Echinaforce(R), an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=32972430|t=2020. Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis.|pdf=|usr=019}}
| |
| − | {{tp|p=32997322|t=2020. COVID-19: Antiviral Agents, Antibody Development and Traditional Chinese Medicine.|pdf=|usr=019}}
| |
| − | {{tp|p=32910347|t=2020. Comparative Antiviral Efficacy of Viral Protease Inhibitors against the Novel SARS-CoV-2 In Vitro.|pdf=|usr=019}}
| |
| − | {{tp|p=32987033|t=2020. Transcription-based drug repurposing for COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32979476|t=2020. Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection.|pdf=|usr=019}}
| |
| − | {{tp|p=32899480|t=2020. Attenuated Influenza Virions Expressing the SARS-CoV-2 Receptor-Binding Domain Induce Neutralizing Antibodies in Mice.|pdf=|usr=019}}
| |
| − | {{tp|p=32993173|t=2020. Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: A Comprehensive Review.|pdf=|usr=019}}
| |
| − | {{tp|p=32993136|t=2020. Network Controllability-Based Prioritization of Candidates for SARS-CoV-2 Drug Repositioning.|pdf=|usr=019}}
| |
| − | {{tp|p=32972027|t=2020. Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak.|pdf=|usr=019}}
| |
| − | {{tp|p=32953852|t=2020. Clinical efficacy of tocilizumab treatment in severe and critical COVID-19 patients.|pdf=|usr=019}}
| |
| − | {{tp|p=32952855|t=2020. Mesenchymal stromal cells as potential immunomodulatory players in severe acute respiratory distress syndrome induced by SARS-CoV-2 infection.|pdf=|usr=019}}
| |
| − | {{tp|p=32952854|t=2020. Off-the-shelf mesenchymal stem cells from human umbilical cord tissue can significantly improve symptoms in COVID-19 patients: An analysis of evidential relations.|pdf=|usr=019}}
| |
| − | {{tp|p=32882767|t=2020. Use of Darunavir-Cobicistat as a Treatment Option for Critically Ill Patients with SARS-CoV-2 Infection.|pdf=|usr=019}}
| |
| − | {{tp|p=32921732|t=2020. Therapeutic strategies against COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32921741|t=2020. Treatments for COVID-19: emerging drugs against the coronavirus - reply.|pdf=|usr=019}}
| |
| − | {{tp|p=32921740|t=2020. Treatments for COVID-19: emerging drugs against the coronavirus.|pdf=|usr=019}}
| |
| − | {{tp|p=32986604|t=2020. Herd immunization with childhood vaccination may provide protection against COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32985199|t=2020. Immunotherapy Approaches on Innate Immunity for SARS-Cov2.|pdf=|usr=019}}
| |
| − | {{tp|p=32985211|t=2020. Potential therapeutic effects of Resveratrol against SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=32924219|t=2020. An Antioxidant Enzyme Therapeutic for COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32894782|t=2020. Thirty-six COVID-19 cases preventively vaccinated with mumps-measles-rubella vaccine: All mild course.|pdf=|usr=019}}
| |
| − | {{tp|p=32955921|t=2020. Is Interleukin 6 the Right Target in COVID-19 Severe Pneumonia?|pdf=|usr=019}}
| |
| − | {{tp|p=32926809|t=2020. Immunomodulators in COVID-19: Two Sides to Every Coin.|pdf=|usr=019}}
| |
| − | {{tp|p=33021529|t=2020. Tocilizumab-Associated Bowel Perforation in SARS-CoV-2 Infection.|pdf=|usr=019}}
| |
| − | {{tp|p=32683974|t=2020. Gastrointestinal Perforation After Treatment With Tocilizumab : An Unexpected Consequence of COVID-19 Pandemic.|pdf=|usr=019}}
| |
| − | {{tp|p=33015631|t=2020. The successful use of extracorporeal carbon dioxide removal as a rescue therapy in a patient with severe COVID-19 pneumonitis.|pdf=|usr=019}}
| |
| − | {{tp|p=32939952|t=2020. Targeting RNA G-Quadruplex in SARS-CoV-2: A Promising Therapeutic Target for COVID-19?|pdf=|usr=019}}
| |
| − | {{tp|p=32212920|t=2020. Ethics of Conducting Clinical Research in an Outbreak Setting.|pdf=|usr=019}}
| |
| − | {{tp|p=33001206|t=2020. Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within four months after symptom onset.|pdf=|usr=019}}
| |
| − | {{tp|p=32959052|t=2020. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32909956|t=2020. Covid-19: Pharma companies promise not to bow to political pressure to rush vaccine production.|pdf=|usr=019}}
| |
| − | {{tp|p=32907856|t=2020. Covid-19: Oxford researchers halt vaccine trial while adverse reaction is investigated.|pdf=|usr=019}}
| |
| − | {{tp|p=32895223|t=2020. We need better evidence on non-drug interventions for covid-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32972969|t=2020. Covid-19: FDA plans strict vaccine approval criteria, angering Trump.|pdf=|usr=019}}
| |
| − | {{tp|p=32938632|t=2020. Covid 19: Science must come first with vaccine, says former CDC chief.|pdf=|usr=019}}
| |
| − | {{tp|p=32933945|t=2020. Convalescent plasma for covid-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32933902|t=2020. Covid-19: RECOVERY trial will evaluate "antiviral antibody cocktail".|pdf=|usr=019}}
| |
| − | {{tp|p=32917676|t=2020. Update to living systematic review on drug treatments for covid-19.|pdf=|usr=019}}
| |
| − | {{tp|p=33020072|t=2020. Covid-19: how to prioritize worse-off populations in allocating safe and effective vaccines.|pdf=|usr=019}}
| |
| − | {{tp|p=33004419|t=2020. Covid-19: Anti-TNF drug adalimumab to be trialled for patients in the community.|pdf=|usr=019}}
| |
| − | {{tp|p=33004346|t=2020. Covid-19: Vaccine roll out could take a year and will require difficult prioritisation decisions.|pdf=|usr=019}}
| |
| − | {{tp|p=32915473|t=2020. Gold Metallodrugs to Target Coronavirus Proteins: Inhibitory Effects on the Spike-ACE2 Interaction and on PLpro Protease Activity by Auranofin and Gold Organometallics.|pdf=|usr=019}}
| |
| − | {{tp|p=32930481|t=2020. Structure-Activity Relationships of Benzamides and Isoindolines Designed as SARS-CoV Protease Inhibitors Effective against SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=32907357|t=2020. Electrocardiographic QT Intervals in Infants Exposed to Hydroxychloroquine Throughout Gestation.|pdf=|usr=019}}
| |
| − | {{tp|p=32970974|t=2020. Exosomes: Applications in Respiratory Infectious Diseases and Prospects for Coronavirus Disease 2019 (COVID-19).|pdf=|usr=019}}
| |
| − | {{tp|p=32914690|t=2020. Synthesis of exfoliated multilayer graphene and its putative interactions with SARS-CoV-2 virus investigated through computational studies.|pdf=|usr=019}}
| |
| − | {{tp|p=32909925|t=2020. Exploring structural dynamics of the MERS-CoV receptor DPP4 and mutant DPP4 receptors.|pdf=|usr=019}}
| |
| − | {{tp|p=33023417|t=2020. In silico exploration of small-molecule alpha-helix mimetics as inhibitors of SARS-COV-2 attachment to ACE2.|pdf=|usr=019}}
| |
| − | {{tp|p=32901936|t=2020. Targeted therapy strategies against SARS-CoV-2 cell entry mechanisms: A systematic review of in vitro and in vivo studies.|pdf=|usr=019}}
| |
| − | {{tp|p=32914973|t=2020. What Are the Odds of Finding a COVID-19 Drug from a Lab Repurposing Screen?|pdf=|usr=019}}
| |
| − | {{tp|p=32947506|t=2020. Systematic Review and Meta-analysis of the Effectiveness and Safety of Hydroxychloroquine in Treating COVID-19 Patients.|pdf=|usr=019}}
| |
| − | {{tp|p=32909898|t=2020. The Role of Phosphodiesterase-5 Inhibitors in COVID-19: An Exploration of Literature From Similar Pathologies.|pdf=|usr=019}}
| |
| − | {{tp|p=32960147|t=2020. Therapeutic Effectiveness of Interferon-alpha2b Against COVID-19: The Cuban Experience.|pdf=|usr=019}}
| |
| − |
| |
| − | {{tp|p=32961123|t=2020. Hydroxychloroquine early in pregnancy and risk of birth defects.|pdf=|usr=019}}
| |
| − | {{tp|p=32771381|t=2020. Use of remdesivir for pregnant patients with severe novel coronavirus disease 2019.|pdf=|usr=019}}
| |
| − | {{tp|p=32915649|t=2020. Potential mechanism underlying the effect of matrine on COVID-19 patients revealed through network pharmacological approaches and molecular docking analysis.|pdf=|usr=019}}
| |
| − | {{tp|p=32959495|t=2020. Anakinra for COVID-19: how to interpret elevations in serum liver enzymes.|pdf=|usr=019}}
| |
| − | {{tp|p=32951346|t=2020. Reply - "Anakinra for COVID-19: how to interpret elevations in liver enzymes".|pdf=|usr=019}}
| |
| − | {{tp|p=32921881|t=2020. Immunosuppression for COVID-19: repurposing medicines in a pandemic.|pdf=|usr=019}}
| |
| − | {{tp|p=33014319|t=2020. Nanoformulation-Based Antiviral Combination Therapy for Treatment of COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=33014317|t=2020. Effective Anti-SARS-CoV-2 RNA Dependent RNA Polymerase Drugs Based on Docking Methods: The Case of Milbemycin, Ivermectin, and Baloxavir Marboxil.|pdf=|usr=019}}
| |
| − | {{tp|p=32952745|t=2020. How menaquinone-7 deficiency influences mortality and morbidity among COVID-19 patients.|pdf=|usr=019}}
| |
| − | {{tp|p=32958250|t=2020. Potent antiviral effect of silver nanoparticles on SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=32977949|t=2020. Andrographolide and its fluorescent derivative inhibit the main proteases of 2019-nCoV and SARS-CoV through covalent linkage.|pdf=|usr=019}}
| |
| − | {{tp|p=32905794|t=2020. The inorganic polymer, polyphosphate, blocks binding of SARS-CoV-2 spike protein to ACE2 receptor at physiological concentrations.|pdf=|usr=019}}
| |
| − | {{tp|p=32966814|t=2020. AR12 (OSU-03012) suppresses GRP78 expression and inhibits SARS-CoV-2 replication.|pdf=|usr=019}}
| |
| − | {{tp|p=32956643|t=2020. Role of proteolytic enzymes in the COVID-19 infection and promising therapeutic approaches.|pdf=|usr=019}}
| |
| − | {{tp|p=32891697|t=2020. Treatments in Covid-19 patients with pre-existing metabolic dysfunction-associated fatty liver disease: A potential threat for drug-induced liver injury?|pdf=|usr=019}}
| |
| − | {{tp|p=32920170|t=2020. May omega-3 fatty acid dietary supplementation help reduce severe complications in Covid-19 patients?|pdf=|usr=019}}
| |
| − | {{tp|p=32983259|t=2020. Therapeutic mechanism of Toujie Quwen granules in COVID-19 based on network pharmacology.|pdf=|usr=019}}
| |
| − | {{tp|p=32983936|t=2020. Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial.|pdf=|usr=019}}
| |
| − | {{tp|p=32901413|t=2020. A Review on the Serum Electrolytes and Trace Elements Role in the Pathophysiology of COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32921981|t=2020. A Review on Novel Drug Targets and Future Directions for COVID-19 Treatment.|pdf=|usr=019}}
| |
| − | {{tp|p=32962156|t=2020. A Putative Prophylactic Solution for COVID-19: Development of Novel Multiepitope Vaccine Candidate against SARS-COV-2 by Comprehensive Immunoinformatic and Molecular Modelling Approach.|pdf=|usr=019}}
| |
| − | {{tp|p=33012699|t=2020. Valinomycin as a potential antiviral agent against coronaviruses: A review.|pdf=|usr=019}}
| |
| − | {{tp|p=32942152|t=2020. Candesartan could ameliorate the COVID-19 cytokine storm.|pdf=|usr=019}}
| |
| − | {{tp|p=32920514|t=2020. The role of Interleukin 6 inhibitors in therapy of severe COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32920511|t=2020. Can a metabolism-targeted therapeutic intervention successfully subjugate SARS-COV-2? A scientific rational.|pdf=|usr=019}}
| |
| − | {{tp|p=33015160|t=2020. Effects of Short-Term Low-Dose Glucocorticoids for Patients with Mild COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32987828|t=2020. The Impacts of Antivirals on the Coronavirus Genome Structure and Subsequent Pathogenicity, Virus Fitness and Antiviral Design.|pdf=|usr=019}}
| |
| − | {{tp|p=32978962|t=2020. Improving precision and power in randomized trials for COVID-19 treatments using covariate adjustment, for binary, ordinal, and time-to-event outcomes.|pdf=|usr=019}}
| |
| − | {{tp|p=32967116|t=2020. Recognition of Potential COVID-19 Drug Treatments through the Study of Existing Protein-Drug and Protein-Protein Structures: An Analysis of Kinetically Active Residues.|pdf=|usr=019}}
| |
| − | {{tp|p=32947136|t=2020. Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=33007742|t=2020. Role of heterocyclic compounds in SARS and SARS CoV-2 pandemic.|pdf=|usr=019}}
| |
| − | {{tp|p=32927129|t=2020. Is oseltamivir suitable for fighting against COVID-19: In silico assessment, in vitro and retrospective study.|pdf=|usr=019}}
| |
| − | {{tp|p=32992245|t=2020. COVID-19 therapy: What weapons do we bring into battle?|pdf=|usr=019}}
| |
| − | {{tp|p=32916377|t=2020. Silico analysis of interaction between full-length SARS-CoV2 S protein with human Ace2 receptor: Modelling, docking, MD simulation.|pdf=|usr=019}}
| |
| − | {{tp|p=33022567|t=2020. 1,2,4 triazolo[1,5-a] pyrimidin-7-ones as novel SARS-CoV-2 Main protease inhibitors: In silico screening and molecular dynamics simulation of potential COVID-19 drug candidates.|pdf=|usr=019}}
| |
| − | {{tp|p=32941783|t=2020. The Inhibitory Effect of a Coronavirus Spike Protein Fragment with ACE2.|pdf=|usr=019}}
| |
| − | {{tp|p=32761223|t=2020. Earlier the better: convalescent plasma.|pdf=|usr=019}}
| |
| − | {{tp|p=32915971|t=2020. COVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant with congenital heart disease.|pdf=|usr=019}}
| |
| − | {{tp|p=32958120|t=2020. Cardiotoxicity induced by the combination therapy of chloroquine and azithromycin in human embryonic stem cell-derived cardiomyocytes.|pdf=|usr=019}}
| |
| − | {{tp|p=32993622|t=2020. Repurposing existing drugs for COVID-19: an endocrinology perspective.|pdf=|usr=019}}
| |
| − | {{tp|p=33008327|t=2020. Subcutaneous injection of IFN alpha-2b for COVID-19: an observational study.|pdf=|usr=019}}
| |
| − | {{tp|p=32900372|t=2020. Treatment estimands in clinical trials of patients hospitalised for COVID-19: ensuring trials ask the right questions.|pdf=|usr=019}}
| |
| − | {{tp|p=32958495|t=2020. Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults.|pdf=|usr=019}}
| |
| − | {{tp|p=32928868|t=2020. Currently prescribed drugs in the UK that could upregulate or downregulate ACE2 in COVID-19 disease: a systematic review.|pdf=|usr=019}}
| |
| − | {{tp|p=32913008|t=2020. Vimentin as a target for the treatment of COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32981567|t=2020. Pre-exposure prophylaxis during the SARS-CoV-2 pandemic: can PrEP prevent COVID-19-related symptoms?|pdf=|usr=019}}
| |
| − | {{tp|p=32949135|t=2020. Takotsubo cardiomyopathy and COVID-19 infection.|pdf=|usr=019}}
| |
| − | {{tp|p=32997792|t=2020. Superinfections in patients treated with Teicoplanin as anti-SARSCoV2 agent.|pdf=|usr=019}}
| |
| − | {{tp|p=32954492|t=2020. The role of methylprednisolone on preventing disease progression for hospitalized patients with severe COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=33015820|t=2020. The therapeutic potential of targeting ACE2 in COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=33015819|t=2020. Remdesivir-COVID-19: drug interactions in dentistry.|pdf=|usr=019}}
| |
| − | {{tp|p=33015818|t=2020. Vitamin deficiency as risk factor for SARS-CoV-2 infection: correlation with susceptibility and prognosis.|pdf=|usr=019}}
| |
| − | {{tp|p=32965013|t=2020. A contemporary look at COVID-19 medications: available and potentially effective drugs.|pdf=|usr=019}}
| |
| − | {{tp|p=32965012|t=2020. Nutraceuticals as immune-stimulating therapy to fight COVID-19. Combination of elements to improve the efficacy.|pdf=|usr=019}}
| |
| − | {{tp|p=32965010|t=2020. SARS-CoV-2 infection: NLRP3 inflammasome as plausible target to prevent cardiopulmonary complications?|pdf=|usr=019}}
| |
| − | {{tp|p=32894567|t=2020. Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review.|pdf=|usr=019}}
| |
| − | {{tp|p=32894566|t=2020. Prospects for the use of regulators of oxidative stress in the comprehensive treatment of the novel Coronavirus Disease 2019 (COVID-19) and its complications.|pdf=|usr=019}}
| |
| − | {{tp|p=32971536|t=2020. Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings.|pdf=|usr=019}}
| |
| − | {{tp|p=32896184|t=2020. Remdesivir, a remedy or a ripple in severe COVID-19?|pdf=|usr=019}}
| |
| − | {{tp|p=32941780|t=2020. Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=32941741|t=2020. Clinical evaluation of Shufeng Jiedu Capsules combined with umifenovir (Arbidol) in the treatment of common-type COVID-19: a retrospective study.|pdf=|usr=019}}
| |
| − | {{tp|p=33026628|t=2020. Autopsy findings in COVID-19-related deaths: a literature review.|pdf=|usr=019}}
| |
| − | {{tp|p=32985653|t=2020. The iminosugars celgosivir, castanospermine and UV-4 inhibit SARS-CoV-2 replication.|pdf=|usr=019}}
| |
| − | {{tp|p=32991235|t=2020. BCG vaccine: a hope to control COVID-19 pandemic amid crisis.|pdf=|usr=019}}
| |
| − | {{tp|p=32962524|t=2020. COVID-19: benefits and risks of passive immunotherapeutics.|pdf=|usr=019}}
| |
| − | {{tp|p=32931361|t=2020. Prospects for mucosal vaccine: shutting the door on SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=33024459|t=2020. Outlook of IL-6 signaling blockade for COVID-19 pneumonia.|pdf=|usr=019}}
| |
| − | {{tp|p=33012103|t=2020. Vitamin D and COVID-19: It is time to act.|pdf=|usr=019}}
| |
| − | {{tp|p=32988821|t=2020. Captisol and GS-704277, but not GS-441524, are credible mediators of remdesivir's nephrotoxicity.|pdf=|usr=019}}
| |
| − | {{tp|p=32967849|t=2020. Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV2 Infection (COVID-19).|pdf=|usr=019}}
| |
| − | {{tp|p=32950264|t=2020. Coronavirus Disease (COVID-19): Current Status and Prospects for Drug and Vaccine Development.|pdf=|usr=019}}
| |
| − | {{tp|p=32929761|t=2020. Cytokine adsorption in a patient with severe coronavirus disease 2019 related acute respiratory distress syndrome requiring extracorporeal membrane oxygenation therapy: A case report.|pdf=|usr=019}}
| |
| − | {{tp|p=32931136|t=2020. COVID-19 clinical trials: Ethical and scientific consequences of the RECOVERY trial results.|pdf=|usr=019}}
| |
| − | {{tp|p=32980462|t=2020. Evolutionary artificial intelligence based peptide discoveries for effective Covid-19 therapeutics.|pdf=|usr=019}}
| |
| − | {{tp|p=32902869|t=2020. Repurposing Vaccines in the Fight against COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=33007557|t=2020. Druggable targets from coronaviruses for designing new antiviral drugs.|pdf=|usr=019}}
| |
| − | {{tp|p=32980515|t=2020. Identification of a novel orally bioavailable NLRP3 inflammasome inhibitor.|pdf=|usr=019}}
| |
| − | {{tp|p=32940192|t=2020. Probiotics against viruses; COVID-19 is a paper tiger: A Systematic Review.|pdf=|usr=019}}
| |
| − | {{tp|p=32914732|t=2020. Oxytocin as a Potential Adjuvant against COVID-19 Infection.|pdf=|usr=019}}
| |
| − | {{tp|p=32918829|t=2020. QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine: A letter to the editor.|pdf=|usr=019}}
| |
| − | {{tp|p=33022271|t=2020. Can selective serotonin reuptake inhibitors have a neuroprotective effect during COVID-19?|pdf=|usr=019}}
| |
| − | {{tp|p=32931783|t=2020. Curcumin, a traditional spice component, can hold the promise against COVID-19?|pdf=|usr=019}}
| |
| − | {{tp|p=33023332|t=2020. Attenuation of acute and chronic inflammation using compounds derived from plants.|pdf=|usr=019}}
| |
| − | {{tp|p=32911560|t=2020. COVID-19 and Sodium-Glucose Cotransporter 2 Inhibitors: No Fear to Attempt?|pdf=|usr=019}}
| |
| − | {{tp|p=33019838|t=2020. Nano Antiviral Photodynamic Therapy: a Probable Biophysicochemical Management Modality in SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=32915657|t=2020. Are open-source approaches the most efficient way forward for COVID-19 drug discovery?|pdf=|usr=019}}
| |
| − | {{tp|p=32915656|t=2020. Metallo therapeutics for COVID-19. Exploiting metal-based compounds for the discovery of new antiviral drugs.|pdf=|usr=019}}
| |
| − | {{tp|p=32981388|t=2020. Use of hydroxychloroquine for pre-exposure prophylaxis in COVID 19: debate and suggested future course.|pdf=|usr=019}}
| |
| − | {{tp|p=32924650|t=2020. The effect of antivirals on COVID-19: a systematic review.|pdf=|usr=019}}
| |
| − | {{tp|p=32903131|t=2020. Systematic review of the antiviral properties of TRIM56: a potential therapeutic intervention for COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32893686|t=2020. Melatonin as a putative protection against myocardial injury in COVID-19 infection.|pdf=|usr=019}}
| |
| − | {{tp|p=33008280|t=2020. Combining hydroxychloroquine and minocycline: potential role in moderate to severe COVID-19 infection.|pdf=|usr=019}}
| |
| − | {{tp|p=32909843|t=2020. Remdesivir emergency approvals: a comparison of the U.S., Japanese, and EU systems.|pdf=|usr=019}}
| |
| − | {{tp|p=32962468|t=2020. Exploit T cell Immunity for Rapid, Safe and Effective COVID-19 Vaccines.|pdf=|usr=019}}
| |
| − | {{tp|p=32940090|t=2020. Potential effects of vaccinations on the prevention of COVID-19: rationale, clinical evidence, risks, and public health considerations.|pdf=|usr=019}}
| |
| − | {{tp|p=32979398|t=2020. SARS-CoV-2 pathophysiology and its clinical implications: An integrative overview of the pharmacotherapeutic management of COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32966484|t=2020. Inhibitory activities of marine sulfated polysaccharides against SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=33011993|t=2020. Antiviral therapies: advances and perspectives.|pdf=|usr=019}}
| |
| − | {{tp|p=32932537|t=2020. Mercurius solubilis as Genus Epidemicus for the COVID-19 Pandemic.|pdf=|usr=019}}
| |
| − | {{tp|p=32942311|t=2020. Are Adequate Vitamin D Levels Helpful in Fighting COVID-19? A Look at the Evidence.|pdf=|usr=019}}
| |
| − | {{tp|p=32993453|t=2020. COVID-19 vaccine development during pandemic: gap analysis, opportunities, and impact on future emerging infectious disease development strategies.|pdf=|usr=019}}
| |
| − | {{tp|p=32991231|t=2020. Neutralizing antibody response elicited by SARS-CoV-2 receptor-binding domain.|pdf=|usr=019}}
| |
| − | {{tp|p=32991223|t=2020. Considerations on the clinical development of COVID-19 vaccine from trial design perspectives.|pdf=|usr=019}}
| |
| − | {{tp|p=32936732|t=2020. Leveraging on the genomics and immunopathology of SARS-CoV-2 for vaccines development: prospects and challenges.|pdf=|usr=019}}
| |
| − | {{tp|p=32961082|t=2020. Perspectives on development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).|pdf=|usr=019}}
| |
| − | {{tp|p=32951151|t=2020. Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase II Clinical Trial.|pdf=|usr=019}}
| |
| − | {{tp|p=32936438|t=2020. Steroids and COVID-19: We Need a Precision Approach, Not One Size Fits All.|pdf=|usr=019}}
| |
| − | {{tp|p=32957905|t=2020. Immuno-Informatics Quest against COVID-19/SARS-COV-2: Determining Putative T-Cell Epitopes for Vaccine Prediction.|pdf=|usr=019}}
| |
| − | {{tp|p=32914928|t=2020. Interim analysis of an open-label randomized controlled trial evaluating nasal irrigations in non-hospitalized patients with coronavirus disease 2019.|pdf=|usr=019}}
| |
| − | {{tp|p=32960104|t=2020. Cautions and Opportunities for Botanicals in COVID-19 Patients: A Comment on the Position of the French Agency for Food, Environmental and Occupational Health & Safety.|pdf=|usr=019}}
| |
| − | {{tp|p=32963091|t=2020. Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.|pdf=|usr=019}}
| |
| − | {{tp|p=32924964|t=2020. An evidence-based systematic review on emerging therapeutic and preventive strategies to treat novel coronavirus (SARS-CoV-2) during an outbreak scenario.|pdf=|usr=019}}
| |
| − |
| |
| − | {{tp|p=32958718|t=2020. A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=33003552|t=2020. Oxidative Stress and Inflammation in COVID-19-Associated Sepsis: The Potential Role of Anti-Oxidant Therapy in Avoiding Disease Progression.|pdf=|usr=019}}
| |
| − | {{tp|p=32992843|t=2020. Sex and SP-A2 Dependent NAD(H) Redox Alterations in Mouse Alveolar Macrophages in Response to Ozone Exposure: Potential Implications for COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32992775|t=2020. Glutathione Supplementation as an Adjunctive Therapy in COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32967329|t=2020. Implications of Oxidative Stress and Potential Role of Mitochondrial Dysfunction in COVID-19: Therapeutic Effects of Vitamin D.|pdf=|usr=019}}
| |
| − | {{tp|p=32967165|t=2020. Oxidative Stress, Proton Fluxes, and Chloroquine/Hydroxychloroquine Treatment for COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32947974|t=2020. Phototherapy as a Rational Antioxidant Treatment Modality in COVID-19 Management; New Concept and Strategic Approach: Critical Review.|pdf=|usr=019}}
| |
| − | {{tp|p=32972196|t=2020. Clinical evidences on the antiviral properties of macrolide antibiotics in the COVID-19 era and beyond.|pdf=|usr=019}}
| |
| − | {{tp|p=32910955|t=2020. Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses.|pdf=|usr=019}}
| |
| − | {{tp|p=32896566|t=2020. Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry.|pdf=|usr=019}}
| |
| − | {{tp|p=33015361|t=2020. Engineering photonics solutions for COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32981754|t=2020. Bioactive Lipids in COVID-19-Further Evidence.|pdf=|usr=019}}
| |
| − | {{tp|p=32962867|t=2020. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.|pdf=|usr=019}}
| |
| − | {{tp|p=32905011|t=2020. SARS-CoV-2 vaccine research and development: conventional vaccines and biomimetic nanotechnology strategies.|pdf=|usr=019}}
| |
| − | {{tp|p=32916441|t=2020. Fight COVID-19 depression with immunity booster: Curcumin for psychoneuroimmunomodulation.|pdf=|usr=019}}
| |
| − | {{tp|p=32988654|t=2020. Recomendaciones para la prevencion de la desnutricion en pacientes con enfermedad del coronavirus 2019 en seguimiento por atencion primaria: Papel del Control Nutricional.|pdf=|usr=019}}
| |
| − | {{tp|p=32901559|t=2020. In search of a vaccine against COVID-19: implications for nursing practice.|pdf=|usr=019}}
| |
| − | {{tp|p=32809882|t=2020. Lopinavir-Ritonavir Treatment for COVID-19 Infection in Intensive Care Unit: Risk of Bradycardia.|pdf=|usr=019}}
| |
| − | {{tp|p=32847819|t=2020. Cytokine storm release syndrome and the prospects for immunotherapy with COVID-19, part 4: The role of JAK inhibition.|pdf=|usr=019}}
| |
| − | {{tp|p=32819962|t=2020. Steroids in COVID-19: An overview.|pdf=|usr=019}}
| |
| − | {{tp|p=32936689|t=2020. Targeted, Site-Specific, Delivery Vehicles of Therapeutics for COVID-19 Patients. Brief Review.|pdf=|usr=019}}
| |
| − | {{tp|p=32901809|t=2020. The Emergence of Baricitinib: A Story of Tortoises Versus Hares.|pdf=|usr=019}}
| |
| − | {{tp|p=32818962|t=2020. Evaluating the Efficacy of Therapies in COVID-19 Patients.|pdf=|usr=019}}
| |
| − | {{tp|p=32797239|t=2020. Baricitinib as treatment for COVID-19: friend or foe of the pancreas?|pdf=|usr=019}}
| |
| − | {{tp|p=32797237|t=2020. Baricitinib: Impact on COVID-19 coagulopathy?|pdf=|usr=019}}
| |
| − | {{tp|p=32797235|t=2020. Response to Correspondence: Baricitinib as Treatment of COVID-19 Friend or Foe of the Pancreas? Cerda-Contreras et.al.|pdf=|usr=019}}
| |
| − | {{tp|p=32797226|t=2020. Response to Correspondence: Baricitinib - Impact on COVID-19 Coagulopathy? Jorgensen et. al.|pdf=|usr=019}}
| |
| − | {{tp|p=32785710|t=2020. Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With COVID-19 (Metcovid): A Randomised, Double-Blind, Phase IIb, Placebo-Controlled Trial.|pdf=|usr=019}}
| |
| − | {{tp|p=32952047|t=2020. Tocilizumab for COVID-19 Pneumonia in a Patient With Non-Small-cell Lung Cancer Treated With Chemoimmunotherapy.|pdf=|usr=019}}
| |
| − | {{tp|p=32919071|t=2020. Impact of convalescent and nonimmune plasma on mortality of patients with COVID-19: a potential role for antithrombin.|pdf=|usr=019}}
| |
| − | {{tp|p=33007479|t=2020. What is the optimal usage of coronavirus disease 2019 convalescent plasma donations?|pdf=|usr=019}}
| |
| − | {{tp|p=33007478|t=2020. Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=33007475|t=2020. Tocilizumab versus the COVID-19 tempest: all's well that ends well or much ado about nothing?|pdf=|usr=019}}
| |
| − | {{tp|p=33007474|t=2020. 'Impact of convalescent and non-immune plasma on mortality of patients with COVID-19: a potential role for antithrombin': authors' response.|pdf=|usr=019}}
| |
| − | {{tp|p=32922095|t=2020. Reduced Prescription of Baloxavir After Suspected Prevalence of a Baloxavir-Resistant Influenza Virus Strain and the Emergence of SARS-CoV-2 in a Tertiary Hospital in Japan.|pdf=|usr=019}}
| |
| − | {{tp|p=32904117|t=2020. Hydroxychloroquine in COVID-19: The Study Points to Premature Decisions on Efficacy While Bells Ringing for Safety.|pdf=|usr=019}}
| |
| − | {{tp|p=32990986|t=2020. COVID-19: A Catalyst to Accelerate Global Regulatory Transformation.|pdf=|usr=019}}
| |
| − | {{tp|p=32978778|t=2020. PharmGKB Tutorial for Pharmacogenomics of Drugs Potentially Used in the Context of COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32956575|t=2020. The Weight of Evidence From Electrophysiology, Observational, and Cardiovascular End Point Studies Demonstrates the Safety of Azithromycin.|pdf=|usr=019}}
| |
| − | {{tp|p=32955785|t=2020. Risk of Metformin in Patients With Type 2 Diabetes With COVID-19: A Preliminary Retrospective Report.|pdf=|usr=019}}
| |
| − | {{tp|p=32932348|t=2020. Guiding Principles for the Conduct of Observational Critical Care Research for Coronavirus Disease 2019 Pandemics and Beyond: The Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study Registry.|pdf=|usr=019}}
| |
| − | {{tp|p=32984987|t=2020. Superiority of cilostazol among antiplatelet FDA-approved drugs against COVID 19 M(pro) and spike protein: Drug repurposing approach.|pdf=|usr=019}}
| |
| − | {{tp|p=32944968|t=2020. Cholesterol 25-Hydroxylase inhibits SARS-CoV-2 and other coronaviruses by depleting membrane cholesterol.|pdf=|usr=019}}
| |
| − | {{tp|p=33026460|t=2020. The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32912355|t=2020. Vitamin D deficiency in schizophrenia implications for COVID-19 infection.|pdf=|usr=019}}
| |
| − | {{tp|p=32804015|t=2020. A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy.|pdf=|usr=019}}
| |
| − | {{tp|p=33012364|t=2020. Exclusion of Older Adults in COVID-19 Clinical Trials.|pdf=|usr=019}}
| |
| − | {{tp|p=33016032|t=2020. Is androgen deprivation therapy protective against SARS-CoV-2 infection and related complications in prostate cancer patients?|pdf=|usr=019}}
| |
| − | {{tp|p=32991794|t=2020. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.|pdf=|usr=019}}
| |
| − | {{tp|p=32876154|t=2020. Reasons to avoid vitamin D deficiency during COVID-19 pandemic.|pdf=|usr=019}}
| |
| − | {{tp|p=33009120|t=2020. A Potential Antiviral Treatment for COVID-19: Remdesivir.|pdf=|usr=019}}
| |
| − | {{tp|p=33009111|t=2020. A Potential Antiviral Treatment for COVID-19: Remdesivir.|pdf=|usr=019}}
| |
| − | {{tp|p=32896174|t=2020. Response to Comment on "Truncated IV acetylcysteine treatment duration has potential to safely preserve resources during the COVID-19 pandemic".|pdf=|usr=019}}
| |
| − | {{tp|p=32960100|t=2020. Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose.|pdf=|usr=019}}
| |
| − | {{tp|p=32970917|t=2020. Enabling Warp Speed Using the Hypervelocity Innovation Model: A Blue Print for Drug Development in Pandemics.|pdf=|usr=019}}
| |
| − | {{tp|p=32936528|t=2020. Important Pharmacogenetic Information for Drugs Prescribed During the SARS-CoV-2 Infection (COVID-19).|pdf=|usr=019}}
| |
| − | {{tp|p=32926573|t=2020. Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on Mortality in Patients With COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32918792|t=2020. Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=32964653|t=2020. Insights on the evidence of cardiotoxicity of hydroxychloroquine prior and during COVID-19 epidemic.|pdf=|usr=019}}
| |
| − | {{tp|p=32940925|t=2020. Heart transplant recipients with confirmed 2019 novel coronavirus infection: The Detroit experience.|pdf=|usr=019}}
| |
| − | {{tp|p=32918761|t=2020. Treatment with convalescent plasma in solid organ transplant recipients with COVID-19: Experience at large transplant center in New York City.|pdf=|usr=019}}
| |
| − | {{tp|p=32928086|t=2020. In silico modeling of small molecule carboxamides as inhibitors of SARS-CoV 3CL protease: An approach towards combating COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=33001008|t=2020. Analysis of Chinese herbal formulae recommended for COVID-19 in different schemes in China: A data mining Approach.|pdf=|usr=019}}
| |
| − | {{tp|p=32891290|t=2020. A narrative literature review on traditional medicine options for treatment of corona virus disease 2019 (COVID-19).|pdf=|usr=019}}
| |
| − | {{tp|p=32911432|t=2020. Site mapping and small molecule blind docking reveal a possible target site on the SARS-CoV-2 main protease dimer interface.|pdf=|usr=019}}
| |
| − | {{tp|p=32961361|t=2020. Data monitoring committees for clinical trials evaluating treatments of COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32964827|t=2020. Design and in-silico screening of Peptide Nucleic Acid (PNA) inspired novel pronucleotide scaffolds targeting COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32940180|t=2020. The Use of cyclodextrin or its complexes as a potential treatment against the 2019 novel coronavirus. A mini-review.|pdf=|usr=019}}
| |
| − | {{tp|p=32938349|t=2020. Role of novel drug delivery systems in coronavirus disease-2019 (covid-19): time to act now.|pdf=|usr=019}}
| |
| − | {{tp|p=32957889|t=2020. Identification of Main Protease of Coronavirus SARS-CoV-2 (Mpro)Inhibitors from Melissa officinalis.|pdf=|usr=019}}
| |
| − | {{tp|p=32972339|t=2020. Targeting host cell proteases to prevent SARS-CoV-2 invasion.|pdf=|usr=019}}
| |
| − | {{tp|p=32900341|t=2020. Current scenario and future prospect in the management of COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=33019921|t=2020. Potential repurposing of drugs with anti-SARS-CoV-2 activity in preclinical trials: a systematic review.|pdf=|usr=019}}
| |
| − | {{tp|p=32957884|t=2020. Quercetin and its relative therapeutic potential against COVID-19: A retrospective review and prospective overview.|pdf=|usr=019}}
| |
| − | {{tp|p=33003119|t=2020. A brief discussion of the benefit and mechanism of vitamin D supplementation on coronavirus disease 2019.|pdf=|usr=019}}
| |
| − | {{tp|p=32969973|t=2020. Coronavirus disease-19 vaccine development utilizing promising technology.|pdf=|usr=019}}
| |
| − | {{tp|p=33003993|t=2020. Therapeutic Options and Treatment Strategies Against COVID-19 in China.|pdf=|usr=019}}
| |
| − | {{tp|p=33001004|t=2020. Potential Therapeutic Benefits of Dipyridamole in COVID-19 Patients.|pdf=|usr=019}}
| |
| − | {{tp|p=32954998|t=2020. Emergence of human pathogenic Coronaviruses: Lectins as antivirals for SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=32901582|t=2020. Fusion protein targeted antiviral peptides: fragment based drug design (FBDD) guided rational design of dipeptides against SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=32957901|t=2020. Drug Repurposing Approaches: Existing Leads For Novel Threats And Drug Targets.|pdf=|usr=019}}
| |
| − | {{tp|p=32951577|t=2020. Carbohydrate-Binding Agents: Potential of Repurposing for COVID-19 Therapy.|pdf=|usr=019}}
| |
| − | {{tp|p=32962613|t=2020. Progress in Studies on Structural and Remedial Aspects of Newly Born Coronavirus, SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=33009266|t=2020. Tracking a Vaccine and Developing Therapeutics for COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32966232|t=2020. Understanding COVID-19 in the light of epidemic disease described in Unani medicine.|pdf=|usr=019}}
| |
| − | {{tp|p=32914465|t=2020. Why nobody discusses the adverse psychiatric effects of chloroquine in case it might become the future treatment against COVID-19?|pdf=|usr=019}}
| |
| − | {{tp|p=32931359|t=2020. Radiotherapy in the fight against pneumonia associated with SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=32910699|t=2020. A combinatorial approach of a polypharmacological adjuvant 2-deoxy-D-glucose with low dose radiation therapy to quell the cytokine storm in COVID-19 management.|pdf=|usr=019}}
| |
| − | {{tp|p=32909697|t=2020. Targeting SARS CoV2 (Indian isolate) genome with miRNA: An in silico study.|pdf=|usr=019}}
| |
| − | {{tp|p=32568274|t=2020. Hydroxychloroquine and coronavirus disease 2019.|pdf=|usr=019}}
| |
| − | {{tp|p=32842905|t=2020. Physical activity and nutrition guidelines to help with the fight against COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32940656|t=2020. In Vitro Efficacy of a Povidone-Iodine Nasal Antiseptic for Rapid Inactivation of SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=32861315|t=2020. COVID-19 vaccine trials should seek worthwhile efficacy.|pdf=|usr=019}}
| |
| − | {{tp|p=32896293|t=2020. Azithromycin for severe COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32896292|t=2020. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial.|pdf=|usr=019}}
| |
| − | {{tp|p=32795409|t=2020. Inclusion of pregnant women in COVID-19 vaccine development.|pdf=|usr=019}}
| |
| − | {{tp|p=32896275|t=2020. COVID-19 vaccine trials in Africa.|pdf=|usr=019}}
| |
| − | {{tp|p=32896274|t=2020. The Russian vaccine for COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32734625|t=2020. BCG vaccination early in life does not improve COVID-19 outcome of elderly populations, based on nationally reported data.|pdf=|usr=019}}
| |
| − | {{tp|p=32902339|t=2020. Efficacy and safety of ruxolitinib for Covid-19 related acute respiratory distress syndrome in a patient with blastic plasmacytoid dendritic cell neoplasm (leukemic variant).|pdf=|usr=019}}
| |
| − | {{tp|p=32519613|t=2020. Hydroxychloroquine and coronavirus disease 19.|pdf=|usr=019}}
| |
| − | {{tp|p=32783352|t=2020. Antiviral Activity of Nanomaterials against Coronaviruses.|pdf=|usr=019}}
| |
| − | {{tp|p=32972631|t=2020. Point of view: Should COVID-19 patients be supplemented with vitamin D?|pdf=|usr=019}}
| |
| − | {{tp|p=32767936|t=2020. Possible Targets and Therapies of SARS-CoV-2 Infection.|pdf=|usr=019}}
| |
| − | {{tp|p=32838716|t=2020. Drug Discovery by Drug Repurposing: Combating COVID-19 in the 21st Century.|pdf=|usr=019}}
| |
| − | {{tp|p=32844821|t=2020. Systematic Review on Repurposing Use of Favipiravir Against SARS-CoV-2.|pdf=|usr=019}}
| |
| − | {{tp|p=32897660|t=2020. "When Will We Have a Vaccine?" - Understanding Questions and Answers about Covid-19 Vaccination.|pdf=|usr=019}}
| |
| − | {{tp|p=32813942|t=2020. A SARS-CoV-2 mRNA Vaccine - Preliminary Report. Reply.|pdf=|usr=019}}
| |
| − | {{tp|p=32813941|t=2020. A SARS-CoV-2 mRNA Vaccine - Preliminary Report.|pdf=|usr=019}}
| |
| − | {{tp|p=32813940|t=2020. A SARS-CoV-2 mRNA Vaccine - Preliminary Report.|pdf=|usr=019}}
| |
| − | {{tp|p=32905696|t=2020. Audio Interview: Guidelines for Covid-19 Vaccine Deployment.|pdf=|usr=019}}
| |
| − | {{tp|p=32966716|t=2020. Evaluating and Deploying Covid-19 Vaccines - The Importance of Transparency, Scientific Integrity, and Public Trust.|pdf=|usr=019}}
| |
| − |
| |
| − | {{tp|p=32816219|t=2020. Use of Azithromycin in COVID-19: A Cautionary Tale.|pdf=|usr=019}}
| |
| − | {{tp|p=32951190|t=2020. Could Tocilizumab be an Attractive Therapeutic Option for Elderly Patients with Severe COVID-19? A Case Report.|pdf=|usr=019}}
| |
| − | {{tp|p=32838064|t=2020. Remdesivir and its antiviral activity against COVID-19: A systematic review.|pdf=|usr=019}}
| |
| − | {{tp|p=32813879|t=2020. Factors determining COVID-19 pneumonia severity in a country with routine BCG vaccination.|pdf=|usr=019}}
| |
| − | {{tp|p=32202241|t=2020. Therapies used in rheumatology with relevance to coronavirus disease 2019.|pdf=|usr=019}}
| |
| − | {{tp|p=32864377|t=2020. Is the impact of childhood vaccines on coronavirus disease 2019, which is moderate in pediatric patients, possible?|pdf=|usr=019}}
| |
| − | {{tp|p=32864376|t=2020. Current national policies for infant universal bacille Calmette-Guerin vaccination were associated with lower mortality from coronavirus disease 2019.|pdf=|usr=019}}
| |
| − | {{tp|p=32864373|t=2020. An edible vaccine development for coronavirus disease 2019: the concept.|pdf=|usr=019}}
| |
| − | {{tp|p=33010411|t=2020. Digestive Manifestations in Patients Hospitalized with COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32961333|t=2020. Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.|pdf=|usr=019}}
| |
| − | {{tp|p=32426812|t=2020. Reduction of coronavirus burden with mass azithromycin distribution.|pdf=|usr=019}}
| |
| − | {{tp|p=33007473|t=2020. Re: Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients' by Fiolet et al.|pdf=|usr=019}}
| |
| − | {{tp|p=32987193|t=2020. Re: 'Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients' by Fiolet et al.|pdf=|usr=019}}
| |
| − | {{tp|p=32979572|t=2020. Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study.|pdf=|usr=019}}
| |
| − | {{tp|p=32971254|t=2020. Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study.|pdf=|usr=019}}
| |
| − | {{tp|p=32791241|t=2020. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.|pdf=|usr=019}}
| |
| − | {{tp|p=32860964|t=2020. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19).|pdf=|usr=019}}
| |
| − | {{tp|p=32860962|t=2020. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis.|pdf=|usr=019}}
| |
| − | {{tp|p=32792417|t=2020. Convalescent Plasma Therapy for COVID-19: State of the Art.|pdf=|usr=019}}
| |
| − | {{tp|p=32922210|t=2020. Hydroxychloroquine and dexamethasone in COVID-19: who won and who lost?|pdf=|usr=019}}
| |
| − | {{tp|p=32900518|t=2020. Malnutrition and nutritional therapy in patients with SARS-CoV-2 disease.|pdf=|usr=019}}
| |
| − | {{tp|p=32917563|t=2020. Convalescent fecal microbiota transplantation as a possible treatment for COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32905148|t=2020. Convalescent Plasma Therapy and Its Effects On COVID-19 Patient Outcomes: A Systematic Review of Current Literature.|pdf=|usr=019}}
| |
| − | {{tp|p=32983702|t=2020. A Meta-Analysis on the Effects of Hydroxychloroquine on COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32839724|t=2020. Timelines of COVID-19 vaccines.|pdf=|usr=019}}
| |
| − | {{tp|p=33015428|t=2020. Biosurfactants and anti-inflammatory activity: A potential new approach towards COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32923374|t=2020. Potential use of polyphenols in the battle against COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32938545|t=2020. AntagomiRs: A novel therapeutic strategy for challenging COVID-19 cytokine storm.|pdf=|usr=019}}
| |
| − | {{tp|p=32948440|t=2020. Glycogen synthase kinase-3: A putative target to combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.|pdf=|usr=019}}
| |
| − | {{tp|p=32895645|t=2020. Tocilizumab for severe COVID-19 related illness - A community academic medical center experience.|pdf=|usr=019}}
| |
| − | {{tp|p=32905939|t=2020. No benefit of hydroxychloroquine in COVID-19: Results of Systematic Review and Meta-Analysis of Randomized Controlled Trials".|pdf=|usr=019}}
| |
| − | {{tp|p=32927405|t=2020. Balanced nutrition is needed in times of COVID19 epidemic in India: A call for action for all nutritionists and physicians.|pdf=|usr=019}}
| |
| − | {{tp|p=32943897|t=2020. Beneficial Effects of Anti-Oxidative Herbal Medicines in Diabetic Patients Infected with COVID-19: A Hypothesis.|pdf=|usr=019}}
| |
| − | {{tp|p=32949651|t=2020. Hyperglycemia, glucocorticoid therapy, and outcome of COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32946854|t=2020. Use of DPP4 inhibitors in Italy does not correlate with diabetes prevalence among COVID-19 deaths.|pdf=|usr=019}}
| |
| − | {{tp|p=32926957|t=2020. Inpatient use of glucocorticoids may mediate the detrimental effect of new-onset hyperglycemia on COVID-19 severity.|pdf=|usr=019}}
| |
| − | {{tp|p=32922517|t=2020. Dexamethasone in the era of COVID-19: friend or foe? An essay on the effects of dexamethasone and the potential risks of its inadvertent use in patients with diabetes.|pdf=|usr=019}}
| |
| − | {{tp|p=33013251|t=2020. Immunomodulation Through Low-Dose Radiation for Severe COVID-19: Lessons From the Past and New Developments.|pdf=|usr=019}}
| |
| − | {{tp|p=32908842|t=2020. Hydroxychloroquine in a G6PD-Deficient Patient with COVID-19 Complicated by Haemolytic Anaemia: Culprit or Innocent Bystander?|pdf=|usr=019}}
| |
| − | {{tp|p=33011825|t=2020. Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32817221|t=2020. Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo.|pdf=|usr=019}}
| |
| − | {{tp|p=33001138|t=2020. Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial.|pdf=|usr=019}}
| |
| − | {{tp|p=33012348|t=2020. SARS-CoV-2 Vaccine Development: Current Status.|pdf=|usr=019}}
| |
| − | {{tp|p=33017914|t=2020. Alpha-lipoic acid may protect patients with diabetes against COVID-19 infection.|pdf=|usr=019}}
| |
| − | {{tp|p=33017913|t=2020. Can neuromodulation support the fight against the COVID19 pandemic? Transcutaneous non-invasive vagal nerve stimulation as a potential targeted treatment of fulminant acute respiratory distress syndrome.|pdf=|usr=019}}
| |
| − | {{tp|p=33017912|t=2020. A new approach for COVID-19 treatment by micro-RNA.|pdf=|usr=019}}
| |
| − | {{tp|p=33017910|t=2020. Defensin 5 for prevention of SARS-CoV-2 invasion and Covid-19 disease.|pdf=|usr=019}}
| |
| − | {{tp|p=33017909|t=2020. Could aquaporin modulators be employed as prospective drugs for COVID-19 related pulmonary comorbidity?|pdf=|usr=019}}
| |
| − | {{tp|p=33017907|t=2020. Infection-iron interaction during COVID-19 pandemic: Time to re-design iron supplementation programs.|pdf=|usr=019}}
| |
| − | {{tp|p=33017906|t=2020. Exercise as medicine for COVID-19: On PPAR with emerging pharmacotherapy.|pdf=|usr=019}}
| |
| − | {{tp|p=33017904|t=2020. Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=33022293|t=2020. Clinical trial protocols of repurposed prophylaxis for COVID-19: a review.|pdf=|usr=019}}
| |
| − | {{tp|p=33027420|t=2020. COVID-19: molecular targets, drug repurposing and new avenues for drug discovery.|pdf=|usr=019}}
| |
| − | {{tp|p=33027419|t=2020. Flavonoid glycosides and their putative human metabolites as potential inhibitors of the SARS-CoV-2 main protease (Mpro) and RNA-dependent RNA polymerase (RdRp).|pdf=|usr=019}}
| |
| − | {{tp|p=33016666|t=2020. Quercetin Phytosome(R) as a potential candidate for managing COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=33009401|t=2020. SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate.|pdf=|usr=019}}
| |
| − | {{tp|p=33025261|t=2020. A Systems Biology Workflow for Drug and Vaccine Repurposing: Identifying Small-Molecule BCG Mimics to Reduce or Prevent COVID-19 Mortality.|pdf=|usr=019}}
| |
| − | {{tp|p=33023033|t=2020. COVID-19: Current Developments and Further Opportunities in Drug Delivery and Therapeutics.|pdf=|usr=019}}
| |
| − | {{tp|p=32978861|t=2020. Preparing for COVID-19 vaccine safety surveillance: A United States perspective.|pdf=|usr=019}}
| |
| − | {{tp|p=33006138|t=2020. Acetylcysteine for the Treatment of Suspected Remdesivir-Associated Acute Liver Failure in COVID-19: A Case Series.|pdf=|usr=019}}
| |
| − | {{tp|p=33006163|t=2020. Coagulopathy, Venous Thromboembolism, and Anticoagulation in Patients with COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=33024017|t=2020. Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines.|pdf=|usr=019}}
| |
| − | {{tp|p=32936918|t=2020. COVID-19 & Hydroxychloroquine side-effects: Glucose 6-phosphate dehydrogenase deficiency (G6PD) and acute haemolytic anaemia.|pdf=|usr=019}}
| |
| − | {{tp|p=32942307|t=2020. Can Glycine Mitigate COVID-19 Associated Tissue Damage and Cytokine Storm?|pdf=|usr=019}}
| |
| − | {{tp|p=32954552|t=2020. Severe COVID-19 and interleukin-6 receptor antagonist tocilizumab: Some notes of concern.|pdf=|usr=019}}
| |
| − | {{tp|p=33027439|t=2020. Should ethanol be considered a treatment for COVID-19?|pdf=|usr=019}}
| |
| − | {{tp|p=32969125|t=2020. Azithromycin in viral infections.|pdf=|usr=019}}
| |
| − | {{tp|p=32965078|t=2020. Severe acute respiratory syndrome-coronavirus-2: Current advances in therapeutic targets and drug development.|pdf=|usr=019}}
| |
| − | {{tp|p=32897326|t=2020. Drug Repurposing Study Pinpoints Potential COVID-19 Antivirals.|pdf=|usr=019}}
| |
| − | {{tp|p=32789505|t=2020. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.|pdf=|usr=019}}
| |
| − | {{tp|p=32789500|t=2020. An Inactivated Virus Candidate Vaccine to Prevent COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32880613|t=2020. COVID-19 and mRNA Vaccines-First Large Test for a New Approach.|pdf=|usr=019}}
| |
| − | {{tp|p=32930767|t=2020. Interest in Global COVID-19 Vaccine Alliance Grows.|pdf=|usr=019}}
| |
| − | {{tp|p=32821939|t=2020. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.|pdf=|usr=019}}
| |
| − | {{tp|p=32821934|t=2020. Efficacy of Remdesivir in COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32808972|t=2020. Ethical Considerations for COVID-19 Vaccine Trials in Correctional Facilities.|pdf=|usr=019}}
| |
| − | {{tp|p=32910182|t=2020. Fairly Prioritizing Groups for Access to COVID-19 Vaccines.|pdf=|usr=019}}
| |
| − | {{tp|p=32789501|t=2020. Researchers Strive to Recruit Hard-Hit Minorities Into COVID-19 Vaccine Trials.|pdf=|usr=019}}
| |
| − | {{tp|p=32915201|t=2020. COVID-19 and the Path to Immunity.|pdf=|usr=019}}
| |
| − | {{tp|p=32910154|t=2020. Reassuring the Public and Clinical Community About the Scientific Review and Approval of a COVID-19 Vaccine.|pdf=|usr=019}}
| |
| − | {{tp|p=32876697|t=2020. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.|pdf=|usr=019}}
| |
| − | {{tp|p=32876695|t=2020. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.|pdf=|usr=019}}
| |
| − | {{tp|p=32876694|t=2020. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis.|pdf=|usr=019}}
| |
| − | {{tp|p=32876693|t=2020. Corticosteroids in COVID-19 ARDS: Evidence and Hope During the Pandemic.|pdf=|usr=019}}
| |
| − | {{tp|p=32876689|t=2020. Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial.|pdf=|usr=019}}
| |
| − | {{tp|p=32870268|t=2020. Regulatory Decision-making on COVID-19 Vaccines During a Public Health Emergency.|pdf=|usr=019}}
| |
| − | {{tp|p=32496545|t=2020. Challenge Trials-Could Deliberate Coronavirus Exposure Hasten Vaccine Development?|pdf=|usr=019}}
| |
| − | {{tp|p=32936268|t=2020. Myocardial Injury in COVID-19-Can We Successfully Target Inflammation?-Reply.|pdf=|usr=019}}
| |
| − | {{tp|p=32936267|t=2020. Myocardial Injury in COVID-19-Can We Successfully Target Inflammation?|pdf=|usr=019}}
| |
| − | {{tp|p=32936260|t=2020. Understanding Observational Treatment Comparisons in the Setting of Coronavirus Disease 2019 (COVID-19).|pdf=|usr=019}}
| |
| − | {{tp|p=32936259|t=2020. Hydroxychloroquine, Coronavirus Disease 2019, and QT Prolongation.|pdf=|usr=019}}
| |
| − | {{tp|p=32986099|t=2020. The Exclusion of Older Persons From Vaccine and Treatment Trials for Coronavirus Disease 2019-Missing the Target.|pdf=|usr=019}}
| |
| − | {{tp|p=32910179|t=2020. Effect of Recombinant Human Granulocyte Colony-Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A Randomized Clinical Trial.|pdf=|usr=019}}
| |
| − | {{tp|p=32910155|t=2020. Immune Stimulation With Recombinant Human Granulocyte Colony-Stimulating Factor for Coronavirus Disease 2019 (COVID-19)-Beware of Blind Spots.|pdf=|usr=019}}
| |
| − | {{tp|p=32804187|t=2020. Policy Implications of the Orphan Drug Designation for Remdesivir to Treat COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32930097|t=2020. Protective potential of expectorants against COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32854988|t=2020. Tratamiento farmacologico de la COVID-19: revision narrativa de los Grupos de Trabajo de Enfermedades Infecciosas y Sepsis (GTEIS) y del Grupo de Trabajo de Transfusiones Hemoderivados (GTTH).|pdf=|usr=019}}
| |
| − | {{tp|p=32864815|t=2020. COVID-19 drug repurposing: A review of computational screening methods, clinical trials, and protein interaction assays.|pdf=|usr=019}}
| |
| − | {{tp|p=33003134|t=2020. Effect of sex hormones on coronavirus disease 2019: an analysis of 5,061 laboratory-confirmed cases in South Korea.|pdf=|usr=019}}
| |
| − | {{tp|p=32883053|t=2020. Probiotics in COVID-19 pandemic: when evidence lacks, rationale can still ease the way.|pdf=|usr=019}}
| |
| − | {{tp|p=32780573|t=2020. Racial Disproportionality in Covid Clinical Trials.|pdf=|usr=019}}
| |
| − | {{tp|p=32641838|t=2020. Coronavirus vaccine developers wary of errant antibodies.|pdf=|usr=019}}
| |
| − | {{tp|p=32358594|t=2020. Convalescent serum lines up as first-choice treatment for coronavirus.|pdf=|usr=019}}
| |
| − | {{tp|p=32205870|t=2020. Coronavirus puts drug repurposing on the fast track.|pdf=|usr=019}}
| |
| − | {{tp|p=32884153|t=2020. Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters.|pdf=|usr=019}}
| |
| − | {{tp|p=33017102|t=2020. Is vitamin D deficiency a risk factor for COVID-19 in children?|pdf=|usr=019}}
| |
| − | {{tp|p=32893957|t=2020. The promise and pitfalls of composite endpoints in sepsis and COVID-19 clinical trials.|pdf=|usr=019}}
| |
| − | {{tp|p=32936069|t=2020. Biophotonics in Health Care and Its Relevance in Fighting the Coronavirus Disease.|pdf=|usr=019}}
| |
| − | {{tp|p=32946328|t=2020. Transcatheter Endoluminal Phototherapy as a Possible Adjunct Treatment for Patients with COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=33008960|t=2020. Review on therapeutic targets for COVID-19: insights from cytokine storm.|pdf=|usr=019}}
| |
| − | {{tp|p=32962623|t=2020. The Role of Tocilizumab in Cytokine Storm and Improving Outcomes in COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32962996|t=2020. A treatment that eliminates SARS-CoV-2 replication in human airway epithelial cells and is safe for inhalation as an aerosol in healthy human subjects.|pdf=|usr=019}}
| |
| − |
| |
| − | {{tp|p=33012890|t=2020. Drug Repositioning for COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32979815|t=2020. Identification of novel human USP2 inhibitor and its putative role in treatment of COVID-19 by inhibiting SARS-CoV-2 papain-like (PLpro) protease.|pdf=|usr=019}}
| |
| − | {{tp|p=32913581|t=2020. Unlocking COVID therapeutic targets: A structure-based rationale against SARS-CoV-2, SARS-CoV and MERS-CoV Spike.|pdf=|usr=019}}
| |
| − | {{tp|p=32927092|t=2020. Selecting appropriate endpoints for assessing treatment effects in comparative clinical studies for COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32894156|t=2020. Plasma exchange in critically ill COVID-19 patients improved inflammation, microcirculatory clot formation, and hypotension, thereby improving clinical outcomes: fact or fiction?|pdf=|usr=019}}
| |
| − | {{tp|p=32993751|t=2020. Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation.|pdf=|usr=019}}
| |
| − | {{tp|p=32977854|t=2020. Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series.|pdf=|usr=019}}
| |
| − | {{tp|p=32972429|t=2020. Fibrin-derived peptide Bbeta15-42 (FX06) as salvage treatment in critically ill patients with COVID-19-associated acute respiratory distress syndrome.|pdf=|usr=019}}
| |
| − | {{tp|p=32958060|t=2020. Glucocorticoid therapy does not delay viral clearance in COVID-19 patients.|pdf=|usr=019}}
| |
| − | {{tp|p=32984840|t=2020. Treatment of Critically Ill Coronavirus Disease 2019 Patients With Adjunct Therapeutic Plasma Exchange: A Single-Center Retrospective Case Series.|pdf=|usr=019}}
| |
| − | {{tp|p=32984833|t=2020. Placenta-Derived Cell Therapy to Treat Patients With Respiratory Failure Due to Coronavirus Disease 2019.|pdf=|usr=019}}
| |
| − | {{tp|p=32983745|t=2020. Micronutrients in COVID-19 Positive Pregnancies.|pdf=|usr=019}}
| |
| − | {{tp|p=32963923|t=2020. In Vitro Virucidal Effect of Intranasally Delivered Chlorpheniramine Maleate Compound Against Severe Acute Respiratory Syndrome Coronavirus 2.|pdf=|usr=019}}
| |
| − | {{tp|p=32953365|t=2020. Therapeutic Options for COVID-19: A Review.|pdf=|usr=019}}
| |
| − | {{tp|p=33025718|t=2020. Investigator initiated research in times of COVID-19: Let's go digital!|pdf=|usr=019}}
| |
| − | {{tp|p=32959499|t=2020. Response to Letter to the Editor Regarding: "The Use of Non-Invasive Vagus Nerve Stimulation to Treat Respiratory Symptoms Associated With COVID-19: A Theoretical Hypothesis and Early Clinical Experience".|pdf=|usr=019}}
| |
| − | {{tp|p=32945085|t=2020. Nutrition management for critically and acutely unwell hospitalised patients with coronavirus disease 2019 (COVID-19) in Australia and New Zealand.|pdf=|usr=019}}
| |
| − | {{tp|p=32974671|t=2020. The implications of vitamin D deficiency on COVID-19 for at-risk populations.|pdf=|usr=019}}
| |
| − | {{tp|p=32963376|t=2020. COVID-19 clinical trials: learning from exceptions in the research chaos.|pdf=|usr=019}}
| |
| − | {{tp|p=32934372|t=2020. Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study.|pdf=|usr=019}}
| |
| − | {{tp|p=32913338|t=2020. Developing COVID-19 vaccines.|pdf=|usr=019}}
| |
| − | {{tp|p=32839620|t=2020. Vaccines targeting SARS-CoV-2 tested in humans.|pdf=|usr=019}}
| |
| − | {{tp|p=32699874|t=2020. Rocaglamide and silvestrol: a long story from anti-tumor to anti-coronavirus compounds.|pdf=|usr=019}}
| |
| − | {{tp|p=32787584|t=2020. Rapid determination and optimisation of berberine from Himalayan Berberis lycium by soxhlet apparatus using CCD-RSM and its quality control as a potential candidate for COVID-19.|pdf=|usr=019}}
| |
| − | {{tp|p=32887942|t=2020. Evolution of the COVID-19 vaccine development landscape.|pdf=|usr=019}}
| |
| − | {{tp|p=32788747|t=2020. The impact of COVID-19 on kidney transplantation.|pdf=|usr=019}}
| |
| − | {{tp|p=32908295|t=2020. A leading coronavirus vaccine trial is on hold: scientists react.|pdf=|usr=019}}
| |
| − | {{tp|p=32948865|t=2020. Who gets a COVID vaccine first? Access plans are taking shape.|pdf=|usr=019}}
| |
| − | {{tp|p=32934375|t=2020. Researchers highlight 'questionable' data in Russian coronavirus vaccine trial results.|pdf=|usr=019}}
| |
| − | {{tp|p=32929259|t=2020. Scientists relieved as coronavirus vaccine trial restarts - but question lack of transparency.|pdf=|usr=019}}
| |
| − | {{tp|p=32908297|t=2020. The underdog coronavirus vaccines that the world will need if front runners stumble.|pdf=|usr=019}}
| |
| − | {{tp|p=32811981|t=2020. What the immune response to the coronavirus says about the prospects for a vaccine.|pdf=|usr=019}}
| |
| − | {{tp|p=32998157|t=2020. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses.|pdf=|usr=019}}
| |
| − | {{tp|p=32994572|t=2020. COVID vaccine confidence requires radical transparency.|pdf=|usr=019}}
| |
| − | {{tp|p=32978611|t=2020. COVID-vaccine results are on the way - and scientists' concerns are growing.|pdf=|usr=019}}
| |
| − | {{tp|p=32967006|t=2020. SARS-CoV-2 vaccines in development.|pdf=|usr=019}}
| |
| − | {{tp|p=32940950|t=2020. Effects of Exercise on ACE2.|pdf=|usr=019}}
| |
